DNA ENCODING CANINE VON WILLEBRAND FACTOR AND METHODS OF USE

Abstract: The complete sequence of the canine von Willebrand Factor cDNA and deduced amino acid sequence is provided. The mutation which causes von Willebrand's Disease in Scottish Terriers, a single base deletion in exon 4, has also been determined. Methods for detecting carriers of the defective vWF gene are also provided.

Description: DNA ENCODING CANINE VON WILLEBRAND FACTOR AND METHODS OF USE FIELD OF THE INVENTION This invention relates generally to canine von Willebrand factor (vWF), and more particularly, to the gene encoding vWF as well as a genetic defect that causes canine von Willebrand's disease. BIOLOGICAL DEPOSITS SEQUENCE ACCESSION NO. Canine von Willebrand Factor BACKGROUND OF THE INVENTION In both dogs and humans, von Willebrand's disease (vWD) is a bleeding disorder of variable severity that results from a quantitative or qualitative defect in von Willebrand factor (vWF) (Ginsburg, D. et al., Blood 79:2507-2519 (1992); Ruggeri, Z.M., et al., FASEB J 7:308-316 (1993); Dodds, W.J., Mod Vet Pract 681- 686 (1984); Johnson, G.S. et al., JAVMA 176:1261-1263 (1988); Brooks, M., Probl In Vet Med 4:636-646 (1992)). This clotting factor has two known functions, stabilization of Factor VIII (hemophilic factor A) in the blood, and aiding the adhesion of platelets to the subendothelium, which allows them to provide hemostasis more effectively. If the factor is missing or defective, the patient, whether human or dog, may bleed severely. The disease is the most common hereditary bleeding disorder in both species, and is genetically and clinically heterogenous. Three clinical types, called 1 , 2, and 3 (formerly I, II, and III; see Sadler, J.E. et al., Blood 8 .676-679 (1994) for nomenclature changes), have been described. Type 1 vWD is inherited in a dominant, incompletely penetrant fashion. Bleeding appears to be due to the reduced level of vWF rather than a qualitative difference. Although this is the most common form of vWD found in most mammals, and can cause serious bleeding problems, it is generally less severe than the other two types. In addition, a relatively inexpensive vasopressin analog (DDAVP) can help alleviate symptoms (Kraus, K.H. et al., Vet Surg 18:103-109 (1989)). In Type 2 vWD, patients have essentially normal levels of vWF, but the factor is abnormal as determined by specialized tests (Ruggeri, Z.M., et al., FASEB J 7:308-316 (1993); Brooks, M., Probl In Vet Med 4:636-646 (1992)). This type is also inherited in a dominant fashion and has only rarely been described in dogs (Turrentine, M.A., et al., Vet Clin North Am Small Anim Pract 18:275 (1988)). Type 3 vWD is the most severe form of the disease. It is inherited as an autosomal recessive trait, and affected individuals have no detectable vWF in their blood. Serious bleeding episodes require transfusions of blood or cryoprecipitate to supply the missing vWF. Heterozygous carriers have moderately reduced factor concentrations, but generally appear to have normal hemostasis. Scottish terriers have Type 3 vWD (Dodds, W.J., Mod Vet Pract 681-686 (1984); Johnson, G.S. et al., JAVMA 176:1261-1263 (1988)). Homozygotes have no detectable vWF and have a severe bleeding disorder. Heterozygotes have reduced levels of the factor, and are clinically normal (Brooks, M. et al., JAVMA 200:1 123-1127 (1992)). The prevalence of vWD among Scottish terriers including both heterozygotes and homozygotes has been variously estimated from 27-31% (Stokol, T. et al., Res. Vet. Sci. 59:152-155 (1995); Brooks, M., Proc. 9th ACVIM Forum 89-91 (1991)). Currently, detection of affected and carrier Scottish terrier dogs is done by vWF antigen testing (Benson, R.E. et al., Am J Vet Res 44:399-403 (1983); Stokol, T. et al., Res. Vet. Sci. 59:152-155 (1995)) or by coagulation assays (Rosborough, T.K. et al., J. Lab. Clin. Med. 96:47-56 (1980); Read, M.S. et al., J. Lab. Clin. Med. 101 :74-82 (1983)). These procedures yield variable results, as the protein-based tests can be influenced by such things as sample collection, sample handling, estrous, pregnancy, vaccination, age, and hypothyroidism (Strauss, H.S. et al., New Eng J Med 269:1251-1252 (1963); Bloom, A.L., Mayo Clin Proc 66:743-75^ (1991 ); Stirling, Y. et al., Thromb Haemostasis 52:176-182 (1984); Mansell, P.D. et al., Br. Vet. J. 148:329-337 (1992); Avgeris, S. et al., JAVMA 196:921-924 (1990); Panciera, D.P. et al., JAVMA 205:1550-1553 (1994)). Thus, for example, a dog that tests within the normal range on one day, can test within the carrier range on another day. It is therefore difficult for breeders to use this information. It would thus be desirable to provide the nucleic acid sequence encoding canine vWF. It would also be desirable to provide the genetic defect responsible for canine vWD. It would further be desirable to obtain the amino acid sequence of canine vWF. It would also be desirable to provide a method for detecting carriers of the defective vWF gene based on the nucleic acid sequence of the normal and defective vWF gene. SUMMARY OF THE INVENTION The present invention provides a novel purified and isolated nucleic acid sequence encoding canine vWF. A nucleic acid sequence containing the mutation that causes vWD in Scottish terriers, a single-base deletion in exon 4, is also provided. The nucleic acid sequences of the present invention may be used in methods for detecting carriers of the mutation that causes vWD. Such methods may be used by breeders to reduce the frequency of the disease-causing allele and the incidence of disease. In addition, the nucleic acid sequence of the canine vWF provided herein may be used to determine the genetic defect that causes vWD in other breeds as well as other species. Additional objects, advantages, and features of the present invention will become apparent from the following description, taken in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS The various advantages of the present invention will become apparent to one skilled in the art by reading the following specification and by referencing the following drawings in which: Figures 1A-1C is the nucleic acid sequence of the canine von Willebrand factor of the present invention; Figures 2A-2C is a comparison of the human and canine prepro-von Willebrand factor amino acid sequences; Figure 3 provides nucleotide sequencing ladders for the von Willebrand's disease mutation region for normal (clear), carrier, and affected Scottish terriers, the sequences being obtained directly from PCR products derived from genomic DNAs in exon 4; Figure 4 illustrates the results of a method of the present invention used to detect the Scottish terrier vWD mutation; and Figure 5 shows the Scottish terrier pedigree, which in turn illustrates segregation of the mutant and normal vWF alleles. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The cDNA encoding canine von Willebrand Factor (vWF) has been sequenced, and its sequence is set forth in Figures 1A-1C and SEQ ID NO: 1 . The amino acid sequence corresponding to the cDNA of canine vWF has been subsequently deduced and is set forth in Figures 2A-2C and SEQ ID NO: 2. The mutation of the normal vWF gene which causes von Willebrand's Disease (vWD), a deletion at codon 88 of the normal gene resulting in a frameshift, is also provided. The nucleic acid sequences of the present invention may be used in methods for detecting homozygous and heterozygous carriers of the defective vWF gene. In a preferred method of detecting the presence of the von Willebrand allele in canines, DNA samples are first collected by relatively noninvasive techniques, i.e., DNA samples are obtained with minimal penetration into body tissues of the animals to be tested. Common noninvasive tissue sample collection methods may be used and include withdrawing buccal cells via cheek swabs and withdrawing blood samples. Following isolation of the DNA by standard techniques, PCR is performed on the DNA utilizing pre-designed primers that produce enzyme restriction sites on those DNA samples that harbor the defective gene. Treatment of the amplified DNA with appropriate restriction enzymes such as BsE I thus allows one to analyze for the presence of the defective allele. One skilled in the art will appreciate that this method may be applied not only to Scottish terriers, but to other breeds such as Shetland sheepdogs and Dutch Kooikers. Overall, the present invention provides breeders with an accurate, definitive test whereby the uπdesired vWD gene may be eliminated from breeding lines. The current tests used by breeders are protein- based, and as noted previously, the primary difficulty with this type of test is the variability of results due to a variety of factors. The ultimate result of such variability is that an inordinate number of animals fall into an ambiguous grouping whereby carriers and noncarriers cannot be reliably distinguished. The present invention obviates the inherent limitations of protein-based tests by detecting the genetic mutation which causes vWD. As described in Specific Example 1 , the methods of the present invention provide an accurate test for distinguishing noncarriers, homozygous carriers and heterozygous carriers of the defective vWF gene. It will be appreciated that because the vWF cDNA of the present invention is substantially homologous to vWF cDNA throughout the canine species, the nucleic acid sequences of the present invention may be used to detect DNA mutations in other breeds as well. In addition, the canine vWF sequence presented herein potentially in combination with the established human sequence (Genbank Accession No. X04385, Bonthron, D. et al., Nucleic Acids Res. 14:7125-7128 (1986); Mancuso, D.J. et al., Biochemistry 30:253-269 (1989); Meyer, D. et al., Throm Haemostasis 70:99-104 (1993)), may be used to facilitate sequencing of the vWF gene and genetic defects causing vWD, in other mammalian species e.g., by using cross-species PCR methods known by those skilled in the art. It is also within the contemplation of this invention that the isolated and purified nucleic acid sequences of the present invention be incorporated into an appropriate recombinant expression vector, e.g., viral or plasmid, which is capable of transforming an appropriate host cell, either eukaryotic (e.g., mammalian) or prokaryotic (e.g., E. coli). Such DNA may involve alternate nucleic acid forms, such as cDNA, gDNA, and DNA prepared by partial or total chemical synthesis. The DNA may also be accompanied by additional regulatory elements, such as promoters, operators and regulators, which are necessary and/or may enhance the expression of the vWF gene product. In this way, cells may be induced to over-express the vWF gene, thereby generating desired amounts of the target vWF protein. It is further contemplated that the canine vWF polypeptide sequence of the present invention may be utilized to manufacture canine vWF using standard synthetic methods. One skilled in the art will also note that the defective protein encoded by the defective vWF gene of the present invention may also be of use in formulating a complementary diagnostic test for canine vWD that may provide further data in establishing the presence of the defective allele. Thus, production of the defective vWF polypeptide, either through expression in transformed host cells as described above for the active vWF polypeptide or through chemical synthesis, is also contemplated by the present invention. The term "gene" as to referred herein means a nucleic acid which encodes a protein product. The term "nucleic acid" refers to a linear array of nucleotides and nucleosides, such as genomic DNA, cDNA and DNA prepared by partial or total chemical synthesis from nucleotides. The term "encoding" means that the nucleic acid may be transcribed and translated into the desired polypeptide. "Polypeptide" refers to amino acid sequences which comprise both full-length proteins and fragments thereof. "Mutation" as referred to herein includes any alteration in a nucleic acid sequence including, but not limited to, deletions, substitutions and additions. As referred to herein, the term "capable of hybridizing under high stringency conditions" means annealing a strand of DNA complementary to the DNA of interest under highly stringent conditions. Likewise, "capable of hybridizing under low stringency conditions" refers to annealing a strand of DNA complementary to the DNA of interest under low stringency conditions. In the present invention, hybridizing under either high or low stringency conditions would involve hybridizing a nucleic acid sequence (e.g., the complementary sequence to SEQ ID NO: 1 or portion thereof), with a second target nucleic acid sequence. "High stringency conditions" for the annealing process may involve, for example, high temperature and/or low salt content, which disfavor hydrogen bonding contacts among mismatched base pairs. "Low stringency conditions" would involve lower temperature, and/or lower salt concentration than that of high stringency conditions. Such conditions allow for two DNA strands to anneal if substantial, though not near complete complementarity exists between the two strands, as is the case among DNA strands that code for the same protein but differ in sequence due to the degeneracy of the genetic code. Appropriate stringency conditions which promote DNA hybridization, for example, 6X SSC at about 45 °C, followed by a wash of 2X SSC at 50 °C are known to those skilled in the art or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.31-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2X SSC at 50 "C to a high stringency of about 0.2X SSC at 50 °C. In addition, the temperature in the wash step can be increased from low stringency at room temperature, about 22 °C, to high stringency conditions, at about 65 °C. Other stringency parameters are described in Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring NY, (1982), at pp. 387-389; see also Sambrook J. et al., Molecular Cloning: A Laboratory Manual, Second Edition, Volume 2, Cold Spring Harbor Laboratory Press, Cold Spring, NY at pp. 8.46-8.47 (1989). SPECIFIC EXAMPLE 1 Materials And Methods Isolation of RNA. The source of the RNA was a uterus from a Scottish Terrier affected with vWD (factor level < 0.1 % and a clinical bleeder), that was surgically removed because of infection. Spleen tissue was obtained from a Doberman Pinscher affected with vWD that died from dilated cardiomyopathy (factor level 7% and a clinical bleeder). Total RNA was extracted from the tissues using Trizol (Life Technologies, Gaithersburg, MD). The integrity of the RNA was assessed by agarose gel electrophoresis. Design of PCR primer sets. Primers were designed to a few regions of the gene, where sequences from two species were available (Lavergne, J.M. et al., Biochem Biophys Res Common 194:1019-1024 (1993); Bakhshi, M.R. et al., Biochem Biophys Acta 1132:325-328 (1992)). These primers were designed using rules for cross-species' amplifications (Venta et al., "Genes-Specific Universal Mammalian Sequence-Tagged Sites: Application To The Canine Genome" Biochem. Genet. (1996) in press). Most of the primers had to be designed to other regions of the gene using the human sequence alone (Mancuso, D.J. et al., Biochemistry 30:253-269 (1991)). Good amplification conditions were determined by using human and canine genomic DNAs. Reverse Transcriptase-PCR. Total RNA was reverse transcribed using random primers (Bergenhem, N.C.H. et al., PNAS (USA) 89:8789-8802 (1992)). The cDNA was amplified using the primer sets shown to work on canine genomic DNA. DNA Sequence Analysis. Amplification products of the predicted sizes were isolated from agarose gels by adsorption onto silica gel particles using the manufacturer's method (Qiagen, Chatsworth, CA). Sequences were determined using 32 P-5' end-labeled primers and a cycle sequencing kit (United States Biochemical Corp., Cleveland, OH). The sequences of the 5' and 3' untranslated regions were determined after amplification using Marathon™ RACE kits (Clontech, Palo Alto, CA). Sequences were aligned using the Eugene software analysis package (Lark Technologies, Houston, TX). The sequence of the canine intron four was determined from PCR-amplified genomic DNA. Design of a Diagnostic Test. PCR mutagenesis was used to create diagnostic and control BsE I and Sat/96 I restriction enzyme sites for the test. Amplification conditions for the test are: 94 * C, 1 min, 61 * C, 1 min, and 72 ' C, 1 min, for 50 cycles using cheek swab DNA (Richards, B. et al., Human Molecular Genetics 2:159-163 (1992)). Population Survey. DNA was collected from 87 Scottish terriers from 16 pedigrees. DNA was isolated either from blood using standard procedures (Sambrook, J. et al., Cold Harbor Spring Lab, Cold Harbor Spring NY, 2nd Edition, (1989)) or by cheek swab samples (Richards, B. et al., Human Molecular Genetics 2:159-163 (1992)). The genetic status of each animal in the survey was determined using the BsE I test described above. Results Comparison of the canine and human sequences. The alignment of the .canine and human prepro-von Willebrand Factor amino acid sequences is shown in Figures 2A-2C. The location of the Scottish terrier vWD mutation is indicated by the "*". Potential N-glycosylation sites are shown in bold type. The known and postulated integrin binding sites are boxed. Amino acid numbers are shown on the right side of the figure. The human sequence is derived from Genbank accession number X04385 (Bonthron, D. et al., Nucleic Acids Res. 14:7125-7128 (1986)). Overall, 85.1 % sequence identity is seen between the prepro-vWF sequences. The pro-region is slightly less conserved than the mature protein (81.4% vs. 87.5%). There were no other noteworthy percentage sequence identity differences seen in other regions of the gene, or between the known repeats contained within the gene (data not shown). Fourteen potential N-linked glycosylation sites are present in the canine sequence, all of which correspond to similar sites contained within the human sequence. The two integrin binding sites identified in the human vWF protein sequence (Lankhof, H. et al., Blood 86:1035- 1042 (1995)) are conserved in the canine sequence as well (Figures 2A-2C). The 5' and 3' untranslated regions have diverged to a greater extent than the coding region (data not shown), comparable to that found between the human and bovine sequences derived for the 5' flanking region (Janel, N. et al., Gene 167:291-295 (1995)). Additional insights into the structure and function of the von Willebrand factor can be gained by comparison of the complete human sequence (Mancuso, D.J. et al., Biochemistry 30:253-269 (1989); Meyer, D. et al., Throm Haemostasis 70:99-104 (1993)) and the complete canine sequence reported here. The sequence for most of exon 28 was determined (Mancuso, D.J. et al., Thromb Haemost 69:980 (1993); Porter, C.A. et al., Mol Phylogenet Evol 5:89-101 (1996)). All three sequences are in complete agreement, although two silent variants have been found in other breeds (Table 1 , exon 28). Partial sequences of exons 40 and 41 (cDNA nucleotide numbers 6923 to 7155, from the initiation codon) were also determined as part of the development of a polymorphic simple tandem repeat genetic marker (Shibuya, H. et al., Anim Genet 24:122 (1994)). There is a single nucleotide sequence difference between this sequence ("T") and the sequence of the present invention, ("C") at nucleotide position 6928. Scottish Terrier vWD mutation. Figure 3 shows nucleotide sequencing ladders for the von Willebrand's Disease mutation region for normal (clear), carrier, and affected Scottish terriers. The sequences were obtained directly from PCR products derived from genomic DNAs in exon 4. The arrowheads show the location of the C nucleotide that is deleted in the disease-causing allele. Note that in the carrier ladder each base above the point of the mutation has a doublet appearance, as predicted for deletion mutations. The factor levels reported for these animals were: Normal, 54%; Carrier, 34%; Affected, <0.1%. As a result of the deletion, a frameshift mutation at codon 88 leads to a new stop codon 103 bases downstream. The resulting severely truncated protein of 119 amino acids does not include any of the mature von Willebrand factor region. The identity of the base in the normal allele was determined from an unaffected dog. Development of a diagnostic test. A PCR primer was designed to produce a BsE I site in the mutant allele but not in the normal allele (Figure 4). The position of the deleted nucleotide is indicated by an asterisk. The altered nucleotides in each primer are underlined. The normal and mutant allele can also be distinguished using Sat/96 I. The naturally occurring Saι/96 I sites are shown by double underlines. The highly conserved donor and acceptor dinucleotide splice sequences are shown in bold type. In order to ensure that the restriction enzyme cut the amplified DNA to completion, an internal control restriction site common to both alleles was designed into the non-diagnostic primer. The test was verified by digestion of the DNA from animals that were affected, obligate carriers, or normal (based on high factor levels [greater than 100% of normal] obtained from commonly used testing labs and reported to us by the owners, and also using breeds in which Type 3 vWD has not been observed). The expected results were obtained (e.g., Figure 5). Five vWD- affected animals from a colony founded from Scottish terriers (Brinkhous, K.M. et al., Ann. New York Acad. Sci. 370:191-203 (1981)) were also shown to be homozygous for this mutation. An additional unaffected animal from this same colony was found to be clear. It would still be possible to misinterpret the results of the test if restriction enzyme digestion was not complete, and if the rates of cleavage of the cont778rol and diagnostic sites were vastly different. The rates of cleavage of the two BsE I sites were thus examined by partially digesting the PCR products and running them on capillary electrophoresis. The rates were found to be very nearly equal (the diagnostic site is cut 12% faster than the control site). The mutagenesis primer was also designed to produce a Sau96 I site into the normal allele but not the mutant allele. This is the reverse relationship compared to the BsE l-dependent test, with respect to which allele is cut. Natural internal Sau96 I sites serve as digestion control sites (shown in Figure 4). The test using this enzyme produced identical genotypic results compared to the BsE I for all animals examined (data not shown). A possible mutation in the Doberman Pinscher gene. The complete Scottish terrier sequence was compared to the complete Doberman Pinscher sequence. Several nucleotide differences were found and were compared to the nucleotides found in the same position in the human sequence as shown in Table 1 below. Most of these changes were silent. However, of three amino acid changes, one is relatively non-conservative (F905L) and is proposed to be the mutation that causes Doberman Pinscher vWD. Other data strongly suggest that the nucleotide interchange at the end of exon 43 causes a cryptic splice site to be activated reducing the amount of normally processed mRNA, with a concomitant decrease in the amount of vWF produced. Mendelian inheritance. One test often used to verify the correct identification of a mutant allele is its inheritance according to Mendel's law of segregation. Three pedigrees were examined in which the normal and mutant alleles were segregating, as shown in Figure 5. Exon four of the vWF gene was PCR-amplified from genomic DNA. The PCR products were examined for the presence of the normal and mutant vWF alleles by agarose gel etectrophoresis after digestion with BsE I (see Figure 5). The affected animals are homozygous for the mutant allele (229 bp; lanes 3 and 5). The other animals in this pedigree are heterozygotes (251 bp and 229 bp; lanes 1 , 2, 4, and 6), including the obligate carrier parents. Table 1 - Differences Between Scottie And Doberman Protein And Nucleotide von Willebrand Factor Sequences With Comparison To The Human Sequences Ammo Acid Codon Exon A A 1 Human Scottie Doberman Human Scottie Doberman 5' UT 2 nuc - 35 ! N/A 4 N/A N/A N/A A G 4 85 S S/F Shift 5 s TCC TCC TC_ TCC 5 173 M R K ATG AGG AAG 11 422 S T T TCC ACA ACC 21 898 C C C TGC TGT TGC 21 905 F F L TTT TTC TTA 24 1041 S S S TCA TCA TCG 24 1042 s s s TCC TCC TCA 28 1333 D D E GAC GAC GAG 28 1349 Y Y Y TAT TAT TAC * 42 2381 P L P CCC CTG CCG 43 2479 S s s TCG TCG TCA 45 2555 P P P CCC CCC CCG 47 2591 P P P CCC CCT CCC 49 2672 D D D GAT GAT GAC 51 2744 E E E GAG GAG GAA 'Amino acid residue position ■ "Untranslated region 3 Nucleotide position 4 Not Applicable s Frameshift mutation Boxed residues show amino acid differences between breeds This site has been shown to be polymorphic in some breeds The mature VWF protein begins in exon 18 The alleles, as typed by both the BsE I and Sau96 I tests, showed no inconsistencies with Mendelian inheritance. One of these pedigrees included two affected animals, two phenotypically normal siblings, and the obligate carrier parents. The two parents were found to be heterozygous by the test, the two affected animals were found to be homozygous for the mutant allele, and the normal siblings were found to be heterozygotes. Population survey for the mutation. Cheek swabs or blood samples were collected from 87 animals in order to determine the incidence of carriers in the U.S. Scottish terrier population. Although we attempted to make the sample as random as possible, these dogs were found to come from 16 pedigrees, several of which are more distantly interconnected. This is due to some ascertainment bias, based on ownership (as opposed to phenotypic ascertainment bias). In these 87 animals four affected and 15 carrier animals were found. Discussion These results establish that the single base deletion found in exon four of the vWF gene causes vWD in the Scottish terrier breed. The protein produced from the mutant allele is extremely short and does not include any of the mature vWF protein. Four Scottish terriers known to be affected with the disease are homozygous for the mutation. Five other mixed-breed dogs descended from Scottish terriers, and affected with vWD, are also homozygous for the mutation. No normal animals are homozygous for the mutation. Unaffected obligate carriers are always heterozygous for the mutation. The gene frequency, as determined from the population survey, appears to be around 0.13 resulting in a heterozygote frequency of about 23% and expected frequency of affected animals of about 2%. Although the sample size is relatively small and somewhat biased, these data are in general agreement with the protein- based surveys (Stokol, T. et al., Res Vet Sci 59:152-155 (1995); Brooks, M., Probl In Vet Med 4:636-646 (1992)), in that the allele frequency is substantial. All data collected thus far indicate that this mutation accounts for essentially all of the von Willebrand's disease found in Scottish terriers. This result is consistent with the results found for other genetic diseases, defined at the molecular level, in various domestic animals (Shuster, D.E. et al., PNAS (USA) 89:9225-9229 (1992); Rudolph, J.A. et al., Nat Genet 2:144-147 (1992); O'Brien, P.J. et al., JAVMA 203:842-851 (1993)). A likely explanation may be found in the pronounced founder effect that occurs in domestic animals, compared to most human and wild animal populations. Published data using the protein-based factor assays have shown that, at least in several instances, obligate carriers have had factor levels that would lead to a diagnosis of "clear" of the disease allele. For example, in one study an obligate carrier had a factor level of 78% (Johnson, G.S. et al., JAVMA 176:1261-1263 (1980)). In another study, at least some of the obligate carriers had factor levels of 65% or greater (Brinkhous, K.M. et al., Ann. New York Acad. Sci. 370:191-203 (1981)). In addition, the number of animals that fall into an equivocal range can be substantial. In one study, 19% of Scottish terriers fell in this range (50-65% of the normal vWF antigen level) (Stokol, T. et al., Res Vet Sci 59:152-155 (1995)). Thus, although the protein-based tests have been useful, the certainty of the DNA-based test described herein should relieve the necessity of repeated testing and the variability associated with the protein-based assays. The mutation is present in the pre-vWF part of the molecule. This part of the molecule is processed off prior to delivery of the mature protein into the plasma. This pre-portion of the molecule is important for the assembly of the mature vWF protein (Verwiej, L. et al., EBMO J 6:2885-2890 (1987); Wise, R.J. et al., Cell 52:229-236 (1988)). With the Scottish terrier frameshift vWD mutation, neither this pre-portion nor any of the mature factor is ever produced, in keeping with the fact that no factor has ever been detected in the blood of affected dogs. The determination of the complete canine vWF cDNA sequence will have an impact upon the development of carrier tests for other breeds and other species as well. Currently, Shetland sheepdogs and Dutch Kooikers are known to have a significant amount of Type 3 vWD (Brooks, M. et al., JAVMA 200:1 123-1 127 (1992); Slappendel, R.J., Vet-Q 17:S21-S22 (1995)). Type 3 vWD has occasionally be seen in other breeds as well (e.g., Johnson, G.S. et al., JAVMA 176:1261-1263 (1980)). All Type 3 vWD mutations described in humans to date have been found within the vWF gene itself. The availability of the canine sequence will make it easier to find the mutations in these breeds. In addition, at least some Type 1 mutations have been found within the human vWF gene, and thus Type 1 mutations may also be found within the vWF gene for breeds affected with that form of the disease. The availability of two divergent mammalian vWF cDNA sequences will also make it much easier to sequence the gene from other mammalian species using cross- species PCR methods (e.g., Venta et al., Biochem. Genet. (1996) in press). The test described herein for the detection of the mutation in Scottish terriers may be performed on small amounts of DNA from any tissue. The tissues that are the least invasive to obtain are blood and buccal cells. For maximum convenience, a cheek swab as a source of DNA is preferred. The foregoing discussion discloses and describes merely exemplary embodiments of the present invention. One skilled in the art will readily recognize from such discussion, and from the accompanying drawings, that various changes, modifications and variations can be made therein without departing from the spirit and scope of the invention. All patents and other publications cited herein are expressly incorporated by reference. SEQUENCE LISTING (1) GENERAL INFORMATION: (l) APPLICANT: Venta, Patrick J Yuzbasiyan-Gurkan, Vilma Schall, William D Brewer, George J (li) TITLE OF INVENTION: DNA ENCODING CANINE VON WILLEBRAND FACTOR AND METHODS OF USE (ill) NUMBER OF SEQUENCES: 2 (lv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Harness, Dickey & Pierce, P.L.C. (B) STREET: 5445 Corporate Drive (C) CITY: Troy (D) STATE: Michigan (E) COUNTRY: USA (F) ZIP: 48098 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Smith, DeAnn F. (C) REFERENCE/DOCKET NUMBER: 211501226PCA (lx) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 248-641-1600 (B) TELEFAX: 248-641-0270 (C) TELEX: 287637 (2) INFORMATION FOR SEQ ID NO : 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8802 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (li) MOLECULE TYPE: cDNA (ill) HYPOTHETICAL: NO (lv) ANTI- SENSE: NO (lx) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 203..8641 (D) OTHER INFORMATION: /function-- "Blood Clotting Protein" /product= "Canine von Willebrand Factor" /standard name= "vWF" (x) PUBLICATION INFORMATION: (A) AUTHORS: Venta, Patrick J. Li, Jianping Yuzbasiyan-Gurkan, Vilma Schall, William D. Brewer, George J. (B) TITLE: Von Willebrand's Disease in the Scottish Terrier is Caused by a Single Base Deletion in Exon Four of the von Willebrand Factor Gene (C) JOURNAL: Journal of the American Veterinary Medicine Association (G) DATE: 1996 (K) RELEVANT RESIDUES IN SEQ ID NO : 1 : FROM 1 TO 8802 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : CATTAAAAGG TCCTGGCTGG GAGCTTTTTT TTGGGACCAG CACTCCATGT TCAAGGGCAA 60 ACAGGGGCCA ATTAGGATCA ATCTTTTTTC TTTCTTTTTT TAAAAAAAAA AATTCTTCCC 120 ACTTTGCACA CGGACAGTAG TACATACCAG TAGCTCTCTG CGAGGACGGT GATCACTAAT 180 CATTTCTCCT GCTTCGTGGC AG ATG AGT CCT ACC AGA CTT GTG AGG GTG CTG 232 Met Ser Pro Thr Arg Leu Val Arg Val Leu 1 5 10 CTG GCT CTG GCC CTC ATC TTG CCA GGG AAA CTT TGT ACA AAA GGG ACT 280 Leu Ala Leu Ala Leu lie Leu Pro Gly Lys Leu Cys Thr Lys Gly Thr 15 20 25 GTT GGA AGG TCA TCG ATG GCC CGA TGT AGC CTT CTC GGA GGT GAC TTC 328 Val Gly Arg Ser Ser Met Ala Arg Cys Ser Leu Leu Gly Gly Asp Phe 30 35 40 ATC AAC ACC TTT GAT GAG AGC ATG TAC AGC TTT GCG GGA GAT TGC AGT 376 lie Asn Thr Phe Asp Glu Ser Met Tyr Ser Phe Ala Gly Asp Cys Ser 45 50 55 TAC CTC CTG GCT GGG GAC TGC CAG GAA CAC TCC ATC TCA CTT ATC GGG 424 Tyr Leu Leu Ala Gly Asp Cys Gin Glu His Ser lie Ser Leu lie Gly 60 65 70 GGT TTC CAA AAT GAC AAA AGA GTG AGC CTC TCC GTG TAT CTC GGA GAA 472 Gly Phe Gin Asn Asp Lys Arg Val Ser Leu Ser Val Tyr Leu Gly Glu 75 80 85 90 TTT TTC GAC ATT CAT TTG TTT GTC AAT GGT ACC ATG CTG CAG GGG ACC 520 Phe Phe Asp lie His Leu Phe Val Asn Gly Thr Met Leu Gin Gly Thr 95 100 105 CAA AGC ATC TCC ATG CCC TAC GCC TCC AAT GGG CTG TAT CTA GAG GCC 568 Gin Ser lie Ser Met Pro Tyr Ala Ser Asn Gly Leu Tyr Leu Glu Ala 110 115 120 GAG GCT GGC TAC TAC AAG CTG TCC AGT GAG GCC TAC GGC TTT GTG GCC 616 Glu Ala Gly Tyr Tyr Lys Leu Ser Ser Glu Ala Tyr Gly Phe Val Ala 125 130 135 AGA ATT GAT GGC AAT GGC AAC TTT CAA GTC CTG CTG TCA GAC AGA TAC 664 Arg lie Asp Gly Asn Gly Asn Phe Gin Val Leu Leu Ser Asp Arg Tyr 140 145 150 TTC AAC AAG ACC TGT GGG CTG TGT GGC AAC TTT AAT ATC TTT GCT GAG 712 Phe Asn Lys Thr Cys Gly Leu Cys Gly Asn Phe Asn lie Phe Ala Glu 155 160 165 170 GAT GAC TTC AAG ACT CAA GAA GGG ACG TTG ACT TCG GAC CCC TAT GAC 760 Asp Asp Phe Lys Thr Gin Glu Gly Thr Leu Thr Ser Asp Pro Tyr Asp 175 180 185 TTT GCC AAC TCC TGG GCC CTG AGC AGT GGG GAA CAA CGG TGC AAA CGG 808 Phe Ala Asn Ser Trp Ala Leu Ser Ser Gly Glu Gin Arg Cys Lys Arg 190 195 200 GTG TCC CCT CCC AGC AGC CCA TGC AAT GTC TCC TCT GAT GAA GTG CAG 856 Val Ser Pro Pro Ser Ser Pro Cys Asn Val Ser Ser Asp Glu Val Gin 205 210 215 CAG GTC CTG TGG GAG CAG TGC CAG CTC CTG AAG AGT GCC TCG GTG TTT 904 Gin Val Leu Trp Glu Gin Cys Gin Leu Leu Lys Ser Ala Ser Val Phe 220 225 230 GCC CGC TGC CAC CCG CTG GTG GAC CCT GAG CCT TTT GTC GCC CTG TGT 952 Ala Arg Cys His Pro Leu Val Asp Pro Glu Pro Phe Val Ala Leu Cys 235 240 245 250 GAA AGG ACT CTG TGC ACC TGT GTC CAG GGG ATG GAG TGC CCT TGT GCG 1000 Glu Arg Thr Leu Cys Thr Cys Val Gin Gly Met Glu Cys Pro Cys Ala 255 260 265 GTC CTC CTG GAG TAC GCC CGG GCC TGT GCC CAG CAG GGG ATT GTC TTG 1048 Val Leu Leu Glu Tyr Ala Arg Ala Cys Ala Gin Gin Gly lie Val Leu 270 275 280 TAC GGC TGG ACC GAC CAC AGC GTC TGC CGA CCA GCA TGC CCT GCT GGC 1096 Tyr Gly Trp Thr Asp His Ser Val Cys Arg Pro Ala Cys Pro Ala Gly 285 290 295 ATG GAG TAC AAG GAG TGC GTG TCC CCT TGC ACC AGA ACT TGC CAG AGC 1144 Met Glu Tyr Lys Glu Cys Val Ser Pro Cys Thr Arg Thr Cys Gin Ser 300 305 310 CTT CAT GTC AAA GAA GTG TGT CAG GAG CAA TGT GTA GAT GGC TGC AGC 1192 Leu His Val Lys Glu Val Cys Gin Glu Gin Cys Val Asp Gly Cys Ser 315 320 325 330 TGC CCC GAG GGC CAG CTC CTG GAT GAA GGC CAC TGC GTG GGA AGT GCT 1240 Cys Pro Glu Gly Gin Leu Leu Asp Glu Gly His Cys Val Gly Ser Ala 335 340 345 GAG TGT TCC TGT GTG CAT GCT GGG CAA CGG TAC CCT CCG GGC GCC TCC 1288 Glu Cys Ser Cys Val His Ala Gly Gin Arg Tyr Pro Pro Gly Ala Ser 350 355 360 CTC TTA CAG GAC TGC CAC ACC TGC ATT TGC CGA AAT AGC CTG TGG ATC 1336 Leu Leu Gin Asp Cys His Thr Cys lie Cys Arg Asn Ser Leu Trp lie 365 370 375 TGC AGC AAT GAA GAA TGC CCA GGC GAG TGT CTG GTC ACA GGA CAG TCC 1384 Cys Ser Asn Glu Glu Cys Pro Gly Glu Cys Leu Val Thr Gly Gin Ser 380 385 390 CAC TTC AAG AGC TTC GAC AAC AGG TAC TTC ACC TTC AGT GGG GTC TGC 1432 His Phe Lys Ser Phe Asp Asn Arg Tyr Phe Thr Phe Ser Gly Val Cys 395 400 405 410 CAC TAC CTG CTG GCC CAG GAC TGC CAG GAC CAC ACA TTC TCT GTT GTC 1480 His Tyr Leu Leu Ala Gin Asp Cys Gin Asp His Thr Phe Ser Val Val 415 420 425 ATA GAG ACT GTC CAG TGT GCC GAT GAC CTG GAT GCT GTC TGC ACC CGC 1528 lie Glu Thr Val Gin Cys Ala Asp Asp Leu Asp Ala Val Cys Thr Arg 430 435 440 TCG GTC ACC GTC CGC CTG CCT GGA CAT CAC AAC AGC CTT GTG AAG CTG 1576 Ser Val Thr Val Arg Leu Pro Gly His His Asn Ser Leu Val Lys Leu 445 450 455 AAG AAT GGG GGA GGA GTC TCC ATG GAT GGC CAG GAT ATC CAG ATT CCT 1624 Lys Asn Gly Gly Gly Val Ser Met Asp Gly Gin Asp He Gin He Pro 460 465 470 CTC CTG CAA GGT GAC CTC CGC ATC CAG CAC ACC GTG ATG GCC TCC GTG 1672 Leu Leu Gin Gly Asp Leu Arg He Gin His Thr Val Met Ala Ser Val 475 480 485 490 CGC CTC AGC TAC GGG GAG GAC CTG CAG ATG GAT TCG GAC GTC CGG GGC 1720 Arg Leu Ser Tyr Gly Glu Asp Leu Gin Met Asp Ser Asp Val Arg Gly 495 500 505 AGG CTA CTG GTG ACG CTG TAC CCC GCC TAC GCG GGG AAG ACG TGC GGC 1768 Arg Leu Leu Val Thr Leu Tyr Pro Ala Tyr Ala Gly Lys Thr Cys Gly 510 515 520 CGT GGC GGG AAC TAC AAC GGC AAC CGG GGG GAC GAC TTC GTG ACG CCC 1816 Arg Gly Gly Asn Tyr Asn Gly Asn Arg Gly Asp Asp Phe Val Thr Pro 525 530 535 GCA GGC CTG GCG GAG CCC CTG GTG GAG GAC TTC GGG AAC GCC TGG AAG 1864 Ala Gly Leu Ala Glu Pro Leu Val Glu Asp Phe Gly Asn Ala Trp Lys 540 545 550 CTG CTC GGG GCC TGC GAG AAC CTG CAG AAG CAG CAC CGC GAT CCC TGC 1912 Leu Leu Gly Ala Cys Glu Asn Leu Gin Lys Gin His Arg Asp Pro Cys 555 560 565 570 AGC CTC AAC CCG CGC CAG GCC AGG TTT GCG GAG GAG GCG TGC GCG CTG 1960 Ser Leu Asn Pro Arg Gin Ala Arg Phe Ala Glu Glu Ala Cys Ala Leu 575 580 585 CTG ACG TCC TCG AAG TTC GAG CCC TGC CAC CGA GCG GTG GGT CCT CAG 2008 Leu Thr Ser Ser Lys Phe Glu Pro Cys His Arg Ala Val Gly Pro Gin 590 595 600 CCC TAC GTG CAG AAC TGC CTC TAC GAC GTC TGC TCC TGC TCC GAC GGC 2056 Pro Tyr Val Gin Asn Cys Leu Tyr Asp Val Cys Ser Cys Ser Asp Gly 605 610 615 AGA GAC TGT CTT TGC AGC GCC GTG GCC AAC TAC GCC GCA GCC GTG GCC 2104 Arg Asp Cys Leu Cys Ser Ala Val Ala Asn Tyr Ala Ala Ala Val Ala 620 625 630 CGG AGG GGC GTG CAC ATC GCG TGG CGG GAG CCG GGC TTC TGT GCG CTG 2152 Arg Arg Gly Val His He Ala Trp Arg Glu Pro Gly Phe Cys Ala Leu 635 640 645 650 AGC TGC CCC CAG GGC CAG GTG TAC CTG CAG TGT GGG ACC CCC TGC AAC 2200 Ser Cys Pro Gin Gly Gin Val Tyr Leu Gin Cys Gly Thr Pro Cys Asn 655 660 665 ATG ACC TGT CTC TCC CTC TCT TAC CCG GAG GAG GAC TGC AAT GAG GTC 2248 Met Thr Cys Leu Ser Leu Ser Tyr Pro Glu Glu Asp Cys Asn Glu Val 670 675 680 TGC TTG GAA AGC TGC TTC TCC CCC CCA GGG CTG TAC CTG GAT GAG AGG 2296 Cys Leu Glu Ser Cys Phe Ser Pro Pro Gly Leu Tyr Leu Asp Glu Arg 685 690 695 GGA GAT TGT GTG CCC AAG GCT CAG TGT CCC TGT TAC TAT GAT GGT GAG 2344 Gly Asp Cys Val Pro Lys Ala Gin Cys Pro Cys Tyr Tyr Asp Gly Glu 700 705 710 ATC TTT CAG CCC GAA GAC ATC TTC TCA GAC CAT CAC ACC ATG TGC TAC 2392 He Phe Gin Pro Glu Asp He Phe Ser Asp His His Thr Met Cys Tyr 715 720 725 730 TGT GAG GAT GGC TTC ATG CAC TGT ACC ACA AGT GGA GGC CTG GGA AGC 2440 Cys Glu Asp Gly Phe Met His Cys Thr Thr Ser Gly Gly Leu Gly Ser 735 740 745 CTG CTG CCC AAC CCG GTG CTC AGC AGC CCC CGG TGT CAC CGC AGC AAA 2488 Leu Leu Pro Asn Pro Val Leu Ser Ser Pro Arg Cys His Arg Ser Lys 750 755 760 AGG AGC CTG TCC TGT CGG CCC CCC ATG GTC AAG TTG GTG TGT CCC GCT 2536 Arg Ser Leu Ser Cys Arg Pro Pro Met Val Lys Leu Val Cys Pro Ala 765 770 775 GAT AAC CCG AGG GCT GAA GGA CTG GAG TGT GCC AAA ACC TGC CAG AAC 2584 Asp Asn Pro Arg Ala Glu Gly Leu Glu Cys Ala Lys Thr Cys Gin Asn 780 785 790 TAT GAC CTG CAG TGC ATG AGC ACA GGC TGT GTC TCC GGC TGC CTC TGC 2632 Tyr Asp Leu Gin Cys Met Ser Thr Gly Cys Val Ser Gly Cys Leu Cys 795 800 805 810 CCG CAG GGC ATG GTC CGG CAT GAA AAC AGG TGT GTG GCG CTG GAA AGA 2680 Pro Gin Gly Met Val Arg His Glu Asn Arg Cys Val Ala Leu Glu Arg 815 820 825 TGT CCC TGC TTC CAC CAA GGC CAA GAG TAC GCC CCA GGA GAA ACC GTG 2728 Cys Pro Cys Phe His Gin Gly Gin Glu Tyr Ala Pro Gly Glu Thr Val 830 835 840 AAA ATT GAC TGC AAC ACT TGT GTC TGT CGG GAC CGG AAG TGG ACC TGC 2776 Lys He Asp Cys Asn Thr Cys Val Cys Arg Asp Arg Lys Trp Thr Cys 845 850 855 ACA GAC CAT GTG TGT GAT GCC ACT TGC TCT GCC ATC GGC ATG GCG CAC 2824 Thr Asp His Val Cys Asp Ala Thr Cys Ser Ala He Gly Met Ala His 860 865 870 TAC CTC ACC TTC GAC GGA CTC AAG TAC CTG TTC CCT GGG GAG TGC CAG 2872 Tyr Leu Thr Phe Asp Gly Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gin 875 880 885 890 TAT GTT CTG GTG CAG GAT TAC TGC GGC AGT AAC CCT GGG ACC TTA CGG 2920 Tyr Val Leu Val Gin Asp Tyr Cys Gly Ser Asn Pro Gly Thr Leu Arg 895 900 905 ATC CTG GTG GGG AAC GAG GGG TGC AGC TAC CCC TCA GTG AAA TGC AAG 2968 He Leu Val Gly Asn Glu Gly Cys Ser Tyr Pro Ser Val Lys Cys Lys 910 915 920 AAG CGG GTC ACC ATC CTG GTG GAA GGA GGA GAG ATT GAA CTG TTT GAT 3016 Lys Arg Val Thr He Leu Val Glu Gly Gly Glu He Glu Leu Phe Asp 925 930 935 GGG GAG GTG AAT GTG AAG AAA CCC ATG AAG GAT GAG ACT CAC TTT GAG 3064 Gly Glu Val Asn Val Lys Lys Pro Met Lys Asp Glu Thr His Phe Glu 940 945 950 GTG GTA GAG TCT GGT CAG TAC GTC ATT CTG CTG CTG GGC AAG GCA CTC 3112 Val Val Glu Ser Gly Gin Tyr Val He Leu Leu Leu Gly Lys Ala Leu 955 960 965 970 TCT GTG GTC TGG GAC CAC CGC CTG AGC ATC TCT GTG ACC CTG AAG CGG 3160 Ser Val Val Trp Asp His Arg Leu Ser He Ser Val Thr Leu Lys Arg 975 980 985 ACA TAC CAG GAG CAG GTG TGT GGC CTG TGT GGG AAT TTT GAT GGC ATC 3208 Thr Tyr Gin Glu Gin Val Cys Gly Leu Cys Gly Asn Phe Asp Gly He 990 995 1000 CAG AAC AAT GAT TTC ACC AGC AGC AGC CTC CAA ATA GAA GAA GAC CCT 3256 Gin Asn Asn Asp Phe Thr Ser Ser Ser Leu Gin He Glu Glu Asp Pro 1005 1010 1015 GTG GAC TTT GGG AAT TCC TGG AAA GTG AAC CCG CAG TGT GCC GAC ACC 3304 Val Asp Phe Gly Asn Ser Trp Lys Val Asn Pro Gin Cys Ala Asp Thr 1020 1025 1030 AAG AAA GTA CCA CTG GAC TCA TCC CCT GCC GTC TGC CAC AAC AAC ATC 3352 Lys Lys Val Pro Leu Asp Ser Ser Pro Ala Val Cys His Asn Asn He 1035 1040 1045 1050 ATG AAG CAG ACG ATG GTG GAT TCC TCC TGC AGG ATC CTC ACC AGT GAT 3400 Met Lys Gin Thr Met Val Asp Ser Ser Cys Arg He Leu Thr Ser Asp 1055 1060 1065 ATT TTC CAG GAC TGC AAC AGG CTG GTG GAC CCT GAG CCA TTC CTG GAC 3448 He Phe Gin Asp Cys Asn Arg Leu Val Asp Pro Glu Pro Phe Leu Asp 1070 1075 1080 ATT TGC ATC TAC GAC ACT TGC TCC TGT GAG TCC ATT GGG GAC TGC ACC 3496 He Cys He Tyr Asp Thr Cys Ser Cys Glu Ser He Gly Asp Cys Thr 1085 1090 1095 TGC TTC TGT GAC ACC ATT GCT GCT TAC GCC CAC GTC TGT GCC CAG CAT 3544 Cys Phe Cys Asp Thr He Ala Ala Tyr Ala His Val Cys Ala Gin His 1100 1105 1110 GGC AAG GTG GTA GCC TGG AGG ACA GCC ACA TTC TGT CCC CAG AAT TGC 3592 Gly Lys Val Val Ala Trp Arg Thr Ala Thr Phe Cys Pro Gin Asn Cys 1115 1120 1125 1130 GAG GAG CGG AAT CTC CAC GAG AAT GGG TAT GAG TGT GAG TGG CGC TAT 3640 Glu Glu Arg Asn Leu His Glu Asn Gly Tyr Glu Cys Glu Trp Arg Tyr 1135 1140 1145 AAC AGC TGT GCC CCT GCC TGT CCC ATC ACG TGC CAG CAC CCC GAG CCA 3688 Asn Ser Cys Ala Pro Ala Cys Pro He Thr Cys Gin His Pro Glu Pro 1150 1155 1160 CTG GCA TGC CCT GTA CAG TGT GTT GAA GGT TGC CAT GCG CAC TGC CCT 3736 Leu Ala Cys Pro Val Gin Cys Val Glu Gly Cys His Ala His Cys Pro 1165 1170 1175 CCA GGG AAA ATC CTG GAT GAG CTT TTG CAG ACC TGC ATC GAC CCT GAA 3784 Pro Gly Lys He Leu Asp Glu Leu Leu Gin Thr Cys He Asp Pro Glu 1180 1185 1190 GAC TGT CCT GTG TGT GAG GTG GCT GGT CGT CGC TTG GCC CCA GGA AAG 3832 Asp Cys Pro Val Cys Glu Val Ala Gly Arg Arg Leu Ala Pro Gly Lys 1195 1200 1205 1210 AAA ATC ATC TTG AAC CCC AGT GAC CCT GAG CAC TGC CAA ATT TGT AAT 3880 Lys He He Leu Asn Pro Ser Asp Pro Glu His Cys Gin He Cys Asn 1215 1220 1225 TGT GAT GGT GTC AAC TTC ACC TGT AAG GCC TGC AGA GAA CCC GGA AGT 3928 Cys Asp Gly Val Asn Phe Thr Cys Lys Ala Cys Arg Glu Pro Gly Ser 1230 1235 1240 GTT GTG GTG CCC CCC ACA GAT GGC CCC ATT GGC TCT ACC ACC TCG TAT 3976 Val Val Val Pro Pro Thr Asp Gly Pro He Gly Ser Thr Thr Ser Tyr 1245 1250 1255 GTG GAG GAC ACG TCG GAG CCG CCC CTC CAT GAC TTC CAC TGC AGC AGG 4024 Val Glu Asp Thr Ser Glu Pro Pro Leu His Asp Phe His Cys Ser Arg 1260 1265 1270 CTT CTG GAC CTG GTT TTC CTG CTG GAT GGC TCC TCC AAG CTG TCT GAG 4072 Leu Leu Asp Leu Val Phe Leu Leu Asp Gly Ser Ser Lys Leu Ser Glu 1275 1280 1285 1290 GAC GAG TTT GAA GTG CTG AAG GTC TTT GTG GTG GGT ATG ATG GAG CAT 4120 Asp Glu Phe Glu Val Leu Lys Val Phe Val Val Gly Met Met Glu His 1295 1300 1305 CTG CAC ATC TCC CAG AAG CGG ATC CGC GTG GCT GTG GTG GAG TAC CAC 4168 Leu His He Ser Gin Lys Arg He Arg Val Ala Val Val Glu Tyr His 1310 1315 1320 GAC GGC TCC CAC GCC TAC ATC GAG CTC AAG GAC CGG AAG CGA CCC TCA 4216 Asp Gly Ser His Ala Tyr He Glu Leu Lys Asp Arg Lys Arg Pro Ser 1325 1330 1335 GAG CTG CGG CGC ATC ACC AGC CAG GTG AAG TAC GCG GGC AGC GAG GTG 4264 Glu Leu Arg Arg He Thr Ser Gin Val Lys Tyr Ala Gly Ser Glu Val 1340 1345 1350 GCC TCC ACC AGT GAG GTC TTA AAG TAC ACG CTG TTC CAG ATC TTT GGC 4312 Ala Ser Thr Ser Glu Val Leu Lys Tyr Thr Leu Phe Gin He Phe Gly 1355 1360 1365 1370 AAG ATC GAC CGC CCG GAA GCG TCT CGC ATT GCC CTG CTC CTG ATG GCC 4360 Lys He Asp Arg Pro Glu Ala Ser Arg He Ala Leu Leu Leu Met Ala 1375 1380 1385 AGC CAG GAG CCC TCA AGG CTG GCC CGG AAT TTG GTC CGC TAT GTG CAG 4408 Ser Gin Glu Pro Ser Arg Leu Ala Arg Asn Leu Val Arg Tyr Val Gin 1390 1395 1400 GGC CTG AAG AAG AAG AAA GTC ATT GTC ATC CCT GTG GGC ATC GGG CCC 4456 Gly Leu Lys Lys Lys Lys Val He Val He Pro Val Gly He Gly Pro 1405 1410 1415 CAC GCC AGC CTT AAG CAG ATC CAC CTC ATA GAG AAG CAG GCC CCT GAG 4504 His Ala Ser Leu Lys Gin He His Leu He Glu Lys Gin Ala Pro Glu 1420 1425 1430 AAC AAG GCC TTT GTG TTC AGT GGT GTG GAT GAG TTG GAG CAG CGA AGG 4552 Asn Lys Ala Phe Val Phe Ser Gly Val Asp Glu Leu Glu Gin Arg Arg 1435 1440 1445 1450 GAT GAG ATT ATC AAC TAC CTC TGT GAC CTT GCC CCC GAA GCA CCT GCC 4600 Asp Glu He He Asn Tyr Leu Cys Asp Leu Ala Pro Glu Ala Pro Ala 1455 1460 1465 CCT ACT CAG CAC CCC CCA ATG GCC CAG GTC ACG GTG GGT TCG GAG CTG 4648 Pro Thr Gin His Pro Pro Met Ala Gin Val Thr Val Gly Ser Glu Leu 1470 1475 1480 TTG GGG GTT TCA TCT CCA GGA CCC AAA AGG AAC TCC ATG GTC CTG GAT 4696 Leu Gly Val Ser Ser Pro Gly Pro Lys Arg Asn Ser Met Val Leu Asp 1485 1490 1495 GTG GTG TTT GTC CTG GAA GGG TCA GAC AAA ATT GGT GAG GCC AAC TTT 4744 Val Val Phe Val Leu Glu Gly Ser Asp Lys He Gly Glu Ala Asn Phe 1500 1505 1510 AAC AAA AGC AGG GAG TTC ATG GAG GAG GTG ATT CAG CGG ATG GAC GTG 4792 Asn Lys Ser Arg Glu Phe Met Glu Glu Val He Gin Arg Met Asp Val 1515 1520 1525 1530 GGC CAG GAC AGG ATC CAC GTC ACA GTG CTG CAG TAC TCG TAC ATG GTG 4840 Gly Gin Asp Arg He His Val Thr Val Leu Gin Tyr Ser Tyr Met Val 1535 1540 1545 ACC GTG GAG TAC ACC TTC AGC GAG GCG CAG TCC AAG GGC GAG GTC CTA 4888 Thr Val Glu Tyr Thr Phe Ser Glu Ala Gin Ser Lys Gly Glu Val Leu 1550 1555 1560 CAG CAG GTG CGG GAT ATC CGA TAC CGG GGT GGC AAC AGG ACC AAC ACT 4936 Gin Gin Val Arg Asp He Arg Tyr Arg Gly Gly Asn Arg Thr Asn Thr 1565 1570 1575 GGA CTG GCC CTG CAA TAC CTG TCC GAA CAC AGC TTC TCG GTC AGC CAG 4984 Gly Leu Ala Leu Gin Tyr Leu Ser Glu His Ser Phe Ser Val Ser Gin 1580 1585 1590 GGG GAC CGG GAG CAG GTA CCT AAC CTG GTC TAC ATG GTC ACA GGA AAC 5032 Gly Asp Arg Glu Gin Val Pro Asn Leu Val Tyr Met Val Thr Gly Asn 1595 1600 1605 1610 CCC GCT TCT GAT GAG ATC AAG CGG ATG CCT GGA GAC ATC CAG GTG GTG 5080 Pro Ala Ser Asp Glu He Lys Arg Met Pro Gly Asp He Gin Val Val 1615 1620 1625 CCC ATC GGG GTG GGT CCA CAT GCC AAT GTG CAG GAG CTG GAG AAG ATT 5128 Pro He Gly Val Gly Pro His Ala Asn Val Gin Glu Leu Glu Lys He 1630 1635 1640 GGC TGG CCC AAT GCC CCC ATC CTC ATC CAT GAC TTT GAG ATG CTC CCT 5176 Gly Trp Pro Asn Ala Pro He Leu He His Asp Phe Glu Met Leu Pro 1645 1650 1655 CGA GAG GCT CCT GAT CTG GTG CTA CAG AGG TGC TGC TCT GGA GAG GGG 5224 Arg Glu Ala Pro Asp Leu Val Leu Gin Arg Cys Cys Ser Gly Glu Gly 1660 1665 1670 CTG CAG ATC CCC ACC CTC TCC CCC ACC CCA GAT TGC AGC CAG CCC CTG 5272 Leu Gin He Pro Thr Leu Ser Pro Thr Pro Asp Cys Ser Gin Pro Leu 1675 1680 1685 1690 GAT GTG GTC CTC CTC CTG GAT GGC TCT TCC AGC ATT CCA GCT TCT TAC 5320 Asp Val Val Leu Leu Leu Asp Gly Ser Ser Ser He Pro Ala Ser Tyr 1695 1700 1705 TTT GAT GAA ATG AAG AGC TTC ACC AAG GCT TTT ATT TCA AGA GCT AAT 5368 Phe Asp Glu Met Lys Ser Phe Thr Lys Ala Phe He Ser Arg Ala Asn 1710 1715 1720 ATA GGG CCC CGG CTC ACT CAA GTG TCG GTG CTG CAA TAT GGA AGC ATC 5 16 He Gly Pro Arg Leu Thr Gin Val Ser Val Leu Gin Tyr Gly Ser He 1725 1730 1735 ACC ACT ATC GAT GTG CCT TGG AAT GTA GCC TAT GAG AAA GTC CAT TTA 5464 Thr Thr He Asp Val Pro Trp Asn Val Ala Tyr Glu Lys Val His Leu 1740 1745 1750 CTG AGC CTT GTG GAC CTC ATG CAG CAG GAG GGA GGC CCC AGC GAA ATT 5512 Leu Ser Leu Val Asp Leu Met Gin Gin Glu Gly Gly Pro Ser Glu He 1755 1760 1765 1770 GGG GAT GCT TTG AGC TTT GCC GTG CGA TAT GTC ACC TCA GAA GTC CAT 5560 Gly Asp Ala Leu Ser Phe Ala Val Arg Tyr Val Thr Ser Glu Val His 1775 1780 1785 GGT GCC AGG CCC GGA GCC TCG AAA GCG GTG GTT ATC CTA GTC ACA GAT 5608 Gly Ala Arg Pro Gly Ala Ser Lys Ala Val Val He Leu Val Thr Asp 1790 1795 1800 GTC TCC GTG GAT TCA GTG GAT GCT GCA GCC GAG GCC GCC AGA TCC AAC 5656 Val Ser Val Asp Ser Val Asp Ala Ala Ala Glu Ala Ala Arg Ser Asn 1805 1810 1815 CGA GTG ACA GTG TTC CCC ATT GGA ATC GGG GAT CGG TAC AGT GAG GCC 5704 Arg Val Thr Val Phe Pro He Gly He Gly Asp Arg Tyr Ser Glu Ala 1820 1825 1830 CAG CTG AGC AGC TTG GCA GGC CCA AAG GCT GGC TCC AAT ATG GTA AGG 5752 G n Leu Ser Ser Leu Ala Gly Pro Lys Ala Gly Ser Asn Met Val Arg 1835 1840 1845 1850 CTC CAG CGA ATT GAA GAC CTC CCC ACC GTG GCC ACC CTG GGA AAT TCC 5800 Leu Gin Arg He Glu Asp Leu Pro Thr Val Ala Thr Leu Gly Asn Ser 1855 1860 1865 TTC TTC CAC AAG CTG TGC TCT GGG TTT GAT AGA GTT TGC GTG GAT GAG 5848 Phe Phe His Lys Leu Cys Ser Gly Phe Asp Arg Val Cys Val Asp Glu 1870 1875 1880 GAT GGG AAT GAG AAG AGG CCC GGG GAT GTC TGG ACC TTG CCA GAC CAG 5896 Asp Gly Asn Glu Lys Arg Pro Gly Asp Val Trp Thr Leu Pro Asp Gin 1885 1890 1895 TGC CAC ACA GTG ACT TGC CTG CCA GAT GGC CAG ACC TTG CTG AAG AGT 5944 Cys His Thr Val Thr Cys Leu Pro Asp Gly Gin Thr Leu Leu Lys Ser 1900 1905 1910 CAT CGG GTC AAC TGT GAC CGG GGG CCA AGG CCT TCG TGC CCC AAT GGC 5992 His Arg Val Asn Cys Asp Arg Gly Pro Arg Pro Ser Cys Pro Asn Gly 1915 1920 1925 1930 CAG CCC CCT CTC AGG GTA GAG GAG ACC TGT GGC TGC CGC TGG ACC TGT 6040 Gin Pro Pro Leu Arg Val Glu Glu Thr Cys Gly Cys Arg Trp Thr Cys 1935 1940 1945 CCC TGT GTG TGC ATG GGC AGC TCT ACC CGG CAC ATC GTG ACC TTT GAT 6088 Pro Cys Val Cys Met Gly Ser Ser Thr Arg His He Val Thr Phe Asp 1950 1955 1960 GGG CAG AAT TTC AAG CTG ACT GGC AGC TGT TCG TAT GTC CTA TTT CAA 6136 Gly Gin Asn Phe Lys Leu Thr Gly Ser Cys Ser Tyr Val Leu Phe Gin 1965 1970 1975 AAC AAG GAG CAG GAC CTG GAG GTG ATT CTC CAG AAT GGT GCC TGC AGC 6184 Asn Lys Glu Gin Asp Leu Glu Val He Leu Gin Asn Gly Ala Cys Ser 1980 1985 1990 CCT GGG GCG AAG GAG ACC TGC ATG AAA TCC ATT GAG GTG AAG CAT GAC 6232 Pro Gly Ala Lys Glu Thr Cys Met Lys Ser He Glu Val Lys His Asp 1995 2000 2005 2010 GGC CTC TCA GTT GAG CTC CAC AGT GAC ATG CAG ATG ACA GTG AAT GGG 6280 Gly Leu Ser Val Glu Leu His Ser Asp Met Gin Met Thr Val Asn Gly 2015 2020 2025 AGA CTA GTC TCC ATC CCA TAT GTG GGT GGA GAC ATG GAA GTC AAT GTT 6328 Arg Leu Val Ser He Pro Tyr Val Gly Gly Asp Met Glu Val Asn Val 2030 2035 2040 TAT GGG ACC ATC ATG TAT GAG GTC AGA TTC AAC CAT CTT GGC CAC ATC 6376 Tyr Gly Thr He Met Tyr Glu Val Arg Phe Asn His Leu Gly His He 2045 2050 2055 TTC ACA TTC ACC CCC CAA AAC AAT GAG TTC CAG CTG CAG CTC AGC CCC 6424 Phe Thr Phe Thr Pro Gin Asn Asn Glu Phe Gin Leu Gin Leu Ser Pro 2060 2065 2070 AGG ACC TTT GCT TCG AAG ACA TAT GGT CTC TGT GGG ATC TGT GAT GAG 6472 Arg Thr Phe Ala Ser Lys Thr Tyr Gly Leu Cys Gly He Cys Asp Glu 2075 2080 2085 2090 AAC GGA GCC AAT GAC TTC ATT CTG AGG GAT GGG ACA GTC ACC ACA GAC 6520 Asn Gly Ala Asn Asp Phe He Leu Arg Asp Gly Thr Val Thr Thr Asp 2095 2100 2105 TGG AAG GCA CTC ATC CAG GAA TGG ACC GTA CAG CAG CTT GGG AAG ACA 6568 Trp Lys Ala Leu He Gin Glu Trp Thr Val Gin Gin Leu Gly Lys Thr 2110 2115 2120 TCC CAG CCT GTC CAT GAG GAG CAG TGT CCT GTC TCC GAA TTC TTC CAC 6616 Ser Gin Pro Val His Glu Glu Gin Cys Pro Val Ser Glu Phe Phe His 2125 2130 2135 TGC CAG GTC CTC CTC TCA GAA TTG TTT GCC GAG TGC CAC AAG GTC CTC 6664 Cys Gin Val Leu Leu Ser Glu Leu Phe Ala Glu Cys His Lys Val Leu 2140 2145 2150 GCT CCA GCC ACC TTT TAT GCC ATG TGC CAG CCC GAC AGT TGC CAC CCG 6712 Ala Pro Ala Thr Phe Tyr Ala Met Cys Gin Pro Asp Ser Cys His Pro 2155 2160 2165 2170 AAG AAA GTG TGT GAG GCG ATT GCC TTG TAT GCC CAC CTC TGT CGG ACC 6760 Lys Lys Val Cys Glu Ala He Ala Leu Tyr Ala His Leu Cys Arg Thr 2175 2180 2185 AAA GGG GTC TGT GTG GAC TGG AGG AGG GCC AAT TTC TGT GCT ATG TCA 6808 Lys Gly Val Cys Val Asp Trp Arg Arg Ala Asn Phe Cys Ala Met Ser 2190 2195 2200 TGT CCA CCA TCC CTG GTG TAC AAC CAC TGT GAG CAT GGC TGC CCT CGG 6856 Cys Pro Pro Ser Leu Val Tyr Asn His Cys Glu His Gly Cys Pro Arg 2205 2210 2215 CTC TGT GAA GGC AAT ACA AGC TCC TGT GGG GAC CAA CCC TCG GAA GGC 6904 Leu Cys Glu Gly Asn Thr Ser Ser Cys Gly Asp Gin Pro Ser Glu Gly 2220 2225 2230 TGC TTC TGC CCC CCA AAC CAA GTC ATG CTG GAA GGT AGC TGT GTC CCC 6952 Cys Phe Cys Pro Pro Asn Gin Val Met Leu Glu Gly Ser Cys Val Pro 2235 2240 2245 2250 GAG GAG GCC TGT ACC CAG TGC ATC AGC GAG GAT GGA GTC CGG CAC CAG 7000 Glu Glu Ala Cys Thr Gin Cys He Ser Glu Asp Gly Val Arg His Gin 2255 2260 2265 TTC CTG GAA ACC TGG GTC CCA GCC CAC CAG CCT TGC CAG ATC TGC ACG 7048 Phe Leu Glu Thr Trp Val Pro Ala His Gin Pro Cys Gin He Cys Thr 2270 2275 2280 TGC CTC AGT GGG CGG AAG GTC AAC TGT ACG TTG CAG CCC TGC CCC ACA 7096 Cys Leu Ser Gly Arg Lys Val Asn Cys Thr Leu Gin Pro Cys Pro Thr 2285 2290 2295 GCC AAA GCT CCC ACC TGT GGC CCG TGT GAA GTG GCC CGC CTC CGC CAG 7144 Ala Lys Ala Pro Thr Cys Gly Pro Cys Glu Val Ala Arg Leu Arg Gin 2300 2305 2310 AAC GCA GTG CAG TGC TGC CCG GAG TAC GAG TGT GTG TGT GAC CTG GTG 7192 Asn Ala Val Gin Cys Cys Pro Glu Tyr Glu Cys Val Cys Asp Leu Val 2315 2320 2325 2330 AGC TGT GAC CTG CCC CCG GTG CCT CCC TGC GAA GAT GGC CTC CAG ATG 7240 Ser Cys Asp Leu Pro Pro Val Pro Pro Cys Glu Asp Gly Leu Gin Met 2335 2340 2345 ACC CTG ACC AAT CCT GGC GAG TGC AGA CCC AAC TTC ACC TGT GCC TGC 7288 Thr Leu Thr Asn Pro Gly Glu Cys Arg Pro Asn Phe Thr Cys Ala Cys 2350 2355 2360 AGG AAG GAT GAA TGC AGA CGG GAG TCC CCG CCC TCT TGT CCC CCG CAC 7336 Arg Lys Asp Glu Cys Arg Arg Glu Ser Pro Pro Ser Cys Pro Pro His 2365 2370 2375 CGG ACG CCG GCC CTT CGG AAG ACT CAG TGC TGT GAT GAG TAT GAG TGT 7384 Arg Thr Pro Ala Leu Arg Lys Thr Gin Cys Cys Asp Glu Tyr Glu Cys 2380 2385 2390 GCA TGC AAC TGT GTC AAC TCC ACG GTG AGC TGC CCG CTT GGG TAC CTG 7432 Ala Cys Asn Cys Val Asn Ser Thr Val Ser Cys Pro Leu Gly Tyr Leu 2395 2400 2405 2410 GCC TCG GCT GTC ACC AAC GAC TGT GGC TGC ACC ACA ACA ACC TGC TTC 7480 Ala Ser Ala Val Thr Asn Asp Cys Gly Cys Thr Thr Thr Thr Cys Phe 2415 2420 2425 CCT GAC AAG GTG TGT GTC CAC CGA GGC ACC ATC TAC CCT GTG GGC CAG 7528 Pro Asp Lys Val Cys Val His Arg Gly Thr He Tyr Pro Val Gly Gin 2430 2435 2440 TTC TGG GAG GAG GCC TGT GAC GTG TGC ACC TGC ACG GAC TTG GAG GAC 7576 Phe Trp Glu Glu Ala Cys Asp Val Cys Thr Cys Thr Asp Leu Glu Asp 2445 2450 2455 TCT GTG ATG GGC CTG CGT GTG GCC CAG TGC TCC CAG AAG CCC TGT GAG 7624 Ser Val Met Gly Leu Arg Val Ala Gin Cys Ser Gin Lys Pro Cys Glu 2460 2465 2470 GAC AAC TGC CTG TCA GGC TTC ACT TAT GTC CTT CAT GAA GGC GAG TGC 7672 Asp Asn Cys Leu Ser Gly Phe Thr Tyr Val Leu His Glu Gly Glu Cys 2475 2480 2485 2490 TGT GGA AGG TGT CTG CCA TCT GCC TGT GAG GTG GTC ACT GGT TCA CCA 7720 Cys Gly Arg Cys Leu Pro Ser Ala Cys Glu Val Val Thr Gly Ser Pro 2495 2500 2505 CGG GGC GAC GCC CAG TCT CAC TGG AAG AAT GTT GGC TCT CAC TGG GCC 7768 Arg Gly Asp Ala Gin Ser His Trp Lys Asn Val Gly Ser His Trp Ala 2510 2515 2520 TCC CCT GAC AAC CCC TGC CTC ATC AAT GAG TGT GTC CGA GTG AAG GAA 7816 Ser Pro Asp Asn Pro Cys Leu He Asn Glu Cys Val Arg Val Lys Glu 2525 2530 2535 GAG GTC TTT GTG CAA CAG AGG AAT GTC TCC TGC CCC CAG CTG AAT GTC 7864 Glu Val Phe Val Gin Gin Arg Asn Val Ser Cys Pro Gin Leu Asn Val 2540 2545 2550 CCC ACC TGC CCC ACG GGC TTC CAG CTG AGC TGT AAG ACC TCA GAG TGT 7912 Pro Thr Cys Pro Thr Gly Phe Gin Leu Ser Cys Lys Thr Ser Glu Cys 2555 2560 2565 2570 TGT CCC ACC TGT CAC TGC GAG CCC CTG GAG GCC TGC TTG CTC AAT GGT 7960 Cys Pro Thr Cys His Cys Glu Pro Leu Glu Ala Cys Leu Leu Asn Gly 2575 2580 2585 ACC ATC ATT GGG CCG GGG AAA AGT CTG ATG ATT GAT GTG TGT ACA ACC 8008 Thr He He Gly Pro Gly Lys Ser Leu Met He Asp Val Cys Thr Thr 2590 2595 2600 TGC CGC TGC ACC GTG CCG GTG GGA GTC ATC TCT GGA TTC AAG CTG GAG 8056 Cys Arg Cys Thr Val Pro Val Gly Val He Ser Gly Phe Lys Leu Glu 2605 2610 2615 GGC AGG AAG ACC ACC TGT GAG GCA TGC CCC CTG GGT TAT AAG GAA GAG 8104 Gly Arg Lys Thr Thr Cys Glu Ala Cys Pro Leu Gly Tyr Lys Glu Glu 2620 2625 2630 AAG AAC CAA GGT GAA TGC TGT GGG AGA TGT CTG CCT ATA GCT TGC ACC 8152 Lys Asn Gin Gly Glu Cys Cys Gly Arg Cys Leu Pro He Ala Cys Thr 2635 2640 2645 2650 ATT CAG CTA AGA GGA GGA CAG ATC ATG ACA CTG AAG CGT GAT GAG ACT 8200 He Gin Leu Arg Gly Gly Gin He Met Thr Leu Lys Arg Asp Glu Thr 2655 2660 2665 ATC CAG GAT GGC TGT GAC AGT CAC TTC TGC AAG GTC AAT GAA AGA GGA 8248 He Gin Asp Gly Cys Asp Ser His Phe Cys Lys Val Asn Glu Arg Gly 2670 2675 2680 GAG TAC ATC TGG GAG AAG AGA GTC ACG GGT TGC CCA CCT TTC GAT GAA 8296 Glu Tyr He Trp Glu Lys Arg Val Thr Gly Cys Pro Pro Phe Asp Glu 2685 2690 2695 CAC AAG TGT CTG GCT GAG GGA GGA AAA ATC ATG AAA ATT CCA GGC ACC 8344 His Lys Cys Leu Ala Glu Gly Gly Lys He Met Lys He Pro Gly Thr 2700 2705 2710 TGC TGT GAC ACA TGT GAG GAG CCA GAA TGC AAG GAT ATC ATT GCC AAG 8392 Cys Cys Asp Thr Cys Glu Glu Pro Glu Cys Lys Asp He He Ala Lys 2715 2720 2725 2730 CTG CAG CGT GTC AAA GTG GGA GAC TGT AAG TCT GAA GAG GAA GTG GAC 8440 Leu Gin Arg Val Lys Val Gly Asp Cys Lys Ser Glu Glu Glu Val Asp 2735 2740 2745 ATT CAT TAC TGT GAG GGT AAA TGT GCC AGC AAA GCC GTG TAC TCC ATC 8488 He His Tyr Cys Glu Gly Lys Cys Ala Ser Lys Ala Val Tyr Ser He 2750 2755 2760 CAC ATG GAG GAT GTG CAG GAC CAG TGC TCC TGC TGC TCG CCC ACC CAG 8536 His Met Glu Asp Val Gin Asp Gin Cys Ser Cys Cys Ser Pro Thr Gin 2765 2770 2775 ACG GAG CCC ATG CAG GTG GCC CTG CGC TGC ACC AAT GGC TCC CTC ATC 8584 Thr Glu Pro Met Gin Val Ala Leu Arg Cys Thr Asn Gly Ser Leu He 2780 2785 2790 TAC CAT GAG ATC CTC AAT GCC ATC GAA TGC AGG TGT TCC CCC AGG AAG 8632 Tyr His Glu He Leu Asn Ala He Glu Cys Arg Cys Ser Pro Arg Lys 2795 2800 2805 2810 TGC AGC AAG TGAGGCCACT GCCTGGATGC TACTGTCGCC TGCCTTACCC 8681 Cys Ser Lys GACCTCACTG GACTGGCCAG AGTGCTGCTC AGTCCTCCTC AGTCCTCCTC CTGCTCTGCT 8741 CTTGTGCTTC CTGATCCCAC AATAAAGGTC AATCTTTCAC CTTGAAAAAA AAAAAAAAAA 8801 A 8802 (2) INFORMATION FOR SEQ ID NO : : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2813 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Ser Pro Thr Arg Leu Val Arg Val Leu Leu Ala Leu Ala Leu He 1 5 10 15 Leu Pro Gly Lys Leu Cys Thr Lys Gly Thr Val Gly Arg Ser Ser Met 20 25 30 Ala Arg Cys Ser Leu Leu Gly Gly Asp Phe He Asn Thr Phe Asp Glu 35 40 45 Ser Met Tyr Ser Phe Ala Gly Asp Cys Ser Tyr Leu Leu Ala Gly Asp 50 55 60 Cys Gin Glu His Ser He Ser Leu He Gly Gly Phe Gin Asn Asp Lys 65 70 75 80 Arg Val Ser Leu Ser Val Tyr Leu Gly Glu Phe Phe Asp He His Leu 85 90 95 Phe Val Asn Gly Thr Met Leu Gin Gly Thr Gin Ser He Ser Met Pro 100 105 110 Tyr Ala Ser Asn Gly Leu Tyr Leu Glu Ala Glu Ala Gly Tyr Tyr Lys 115 120 125 Leu Ser Ser Glu Ala Tyr Gly Phe Val Ala Arg He Asp Gly Asn Gly 130 135 140 Asn Phe Gin Val Leu Leu Ser Asp Arg Tyr Phe Asn Lys Thr Cys Gly 145 150 155 160 Leu Cys Gly Asn Phe Asn He Phe Ala Glu Asp Asp Phe Lys Thr Gin 165 170 175 Glu Gly Thr Leu Thr Ser Asp Pro Tyr Asp Phe Ala Asn Ser Trp Ala 180 185 190 Leu Ser Ser Gly Glu Gin Arg Cys Lys Arg Val Ser Pro Pro Ser Ser 195 200 205 Pro Cys Asn Val Ser Ser Asp Glu Val Gin Gin Val Leu Trp Glu Gin 210 215 220 Cys Gin Leu Leu Lys Ser Ala Ser Val Phe Ala Arg Cys His Pro Leu 225 230 235 240 Val Asp Pro Glu Pro Phe Val Ala Leu Cys Glu Arg Thr Leu Cys Thr 245 250 255 Cys Val Gin Gly Met Glu Cys Pro Cys Ala Val Leu Leu Glu Tyr Ala 260 265 270 Arg Ala Cys Ala Gin Gin Gly He Val Leu Tyr Gly Trp Thr Asp His 275 280 285 Ser Val Cys Arg Pro Ala Cys Pro Ala Gly Met Glu Tyr Lys Glu Cys 290 295 300 Val Ser Pro Cys Thr Arg Thr Cys Gin Ser Leu His Val Lys Glu Val 305 310 315 320 Cys Gin Glu Gin Cys Val Asp Gly Cys Ser Cys Pro Glu Gly Gin Leu 325 330 335 Leu Asp Glu Gly His Cys Val Gly Ser Ala Glu Cys Ser Cys Val His 340 345 350 Ala Gly Gin Arg Tyr Pro Pro Gly Ala Ser Leu Leu Gin Asp Cys His 355 360 365 Thr Cys He Cys Arg Asn Ser Leu Trp He Cys Ser Asn Glu Glu Cys 370 375 380 Pro Gly Glu Cys Leu Val Thr Gly Gin Ser His Phe Lys Ser Phe Asp 385 390 395 400 Asn Arg Tyr Phe Thr Phe Ser Gly Val Cys His Tyr Leu Leu Ala Gin 405 410 415 Asp Cys Gin Asp His Thr Phe Ser Val Val He Glu Thr Val Gin Cys 420 425 430 Ala Asp Asp Leu Asp Ala Val Cys Thr Arg Ser Val Thr Val Arg Leu 435 440 445 Pro Gly His His Asn Ser Leu Val Lys Leu Lys Asn Gly Gly Gly Val 450 455 460 Ser Met Asp Gly Gin Asp He Gin He Pro Leu Leu Gin Gly Asp Leu 465 470 475 480 Arg He Gin His Thr Val Met Ala Ser Val Arg Leu Ser Tyr Gly Glu 485 490 495 Asp Leu Gin Met Asp Ser Asp Val Arg Gly Arg Leu Leu Val Thr Leu 500 505 510 Tyr Pro Ala Tyr Ala Gly Lys Thr Cys Gly Arg Gly Gly Asn Tyr Asn 515 520 525 Gly Asn Arg Gly Asp Asp Phe Val Thr Pro Ala Gly Leu Ala Glu Pro 530 535 540 Leu Val Glu Asp Phe Gly Asn Ala Trp Lys Leu Leu Gly Ala Cys Glu 545 550 555 560 Asn Leu Gin Lys Gin His Arg Asp Pro Cys Ser Leu Asn Pro Arg Gin 565 570 575 Ala Arg Phe Ala Glu Glu Ala Cys Ala Leu Leu Thr Ser Ser Lys Phe 580 585 590 Glu Pro Cys His Arg Ala Val Gly Pro Gin Pro Tyr Val Gin Asn Cys 595 600 605 Leu Tyr Asp Val Cys Ser Cys Ser Asp Gly Arg Asp Cys Leu Cys Ser 610 615 620 Ala Val Ala Asn Tyr Ala Ala Ala Val Ala Arg Arg Gly Val His He 625 630 635 640 Ala Trp Arg Glu Pro Gly Phe Cys Ala Leu Ser Cys Pro Gin Gly Gin 645 650 655 Val Tyr Leu Gin Cys Gly Thr Pro Cys Asn Met Thr Cys Leu Ser Leu 660 665 670 Ser Tyr Pro Glu Glu Asp Cys Asn Glu Val Cys Leu Glu Ser Cys Phe 675 680 685 Ser Pro Pro Gly Leu Tyr Leu Asp Glu Arg Gly Asp Cys Val Pro Lys 690 695 700 Ala Gin Cys Pro Cys Tyr Tyr Asp Gly Glu He Phe Gin Pro Glu Asp 705 710 715 720 He Phe Ser Asp His His Thr Met Cys Tyr Cys Glu Asp Gly Phe Met 725 730 735 His Cys Thr Thr Ser Gly Gly Leu Gly Ser Leu Leu Pro Asn Pro Val 740 745 750 Leu Ser Ser Pro Arg Cys His Arg Ser Lys Arg Ser Leu Ser Cys Arg 755 760 765 Pro Pro Met Val Lys Leu Val Cys Pro Ala Asp Asn Pro Arg Ala Glu 770 775 780 Gly Leu Glu Cys Ala Lys Thr Cys Gin Asn Tyr Asp Leu Gin Cys Met 785 790 795 800 Ser Thr Gly Cys Val Ser Gly Cys Leu Cys Pro Gin Gly Met Val Arg 805 810 815 His Glu Asn Arg Cys Val Ala Leu Glu Arg Cys Pro Cys Phe His Gin 820 825 830 Gly Gin Glu Tyr Ala Pro Gly Glu Thr Val Lys He Asp Cys Asn Thr 835 840 845 Cys Val Cys Arg Asp Arg Lys Trp Thr Cys Thr Asp His Val Cys Asp 850 855 860 Ala Thr Cys Ser Ala He Gly Met Ala His Tyr Leu Thr Phe Asp Gly 865 870 875 880 Leu Lys Tyr Leu Phe Pro Gly Glu Cys Gin Tyr Val Leu Val Gin Asp 885 890 895 Tyr Cys Gly Ser Asn Pro Gly Thr Leu Arg He Leu Val Gly Asn Glu 900 905 910 Gly Cys Ser Tyr Pro Ser Val Lys Cys Lys Lys Arg Val Thr He Leu 915 920 925 Val Glu Gly Gly Glu He Glu Leu Phe Asp Gly Glu Val Asn Val Lys 930 935 940 Lys Pro Met Lys Asp Glu Thr His Phe Glu Val Val Glu Ser Gly Gin 945 950 955 960 Tyr Val He Leu Leu Leu Gly Lys Ala Leu Ser Val Val Trp Asp His 965 970 975 Arg Leu Ser He Ser Val Thr Leu Lys Arg Thr Tyr Gin Glu Gin Val 980 985 990 Cys Gly Leu Cys Gly Asn Phe Asp Gly He Gin Asn Asn Asp Phe Thr 995 1000 1005 Ser Ser Ser Leu Gin He Glu Glu Asp Pro Val Asp Phe Gly Asn Ser 1010 1015 1020 Trp Lys Val Asn Pro Gin Cys Ala Asp Thr Lys Lys Val Pro Leu Asp 1025 1030 1035 1040 Ser Ser Pro Ala Val Cys His Asn Asn He Met Lys Gin Thr Met Val 1045 1050 1055 Asp Ser Ser Cys Arg He Leu Thr Ser Asp He Phe Gin Asp Cys Asn 1060 1065 1070 Arg Leu Val Asp Pro Glu Pro Phe Leu Asp He Cys He Tyr Asp Thr 1075 1080 1085 Cys Ser Cys Glu Ser He Gly Asp Cys Thr Cys Phe Cys Asp Thr He 1090 1095 1100 Ala Ala Tyr Ala His Val Cys Ala Gin His Gly Lys Val Val Ala Trp 1105 1110 1115 1120 Arg Thr Ala Thr Phe Cys Pro Gin Asn Cys Glu Glu Arg Asn Leu His 1125 1130 1135 Glu Asn Gly Tyr Glu Cys Glu Trp Arg Tyr Asn Ser Cys Ala Pro Ala 1140 1145 1150 Cys Pro He Thr Cys Gin His Pro Glu Pro Leu Ala Cys Pro Val Gin 1155 1160 1165 Cys Val Glu Gly Cys His Ala His Cys Pro Pro Gly Lys He Leu Asp 1170 1175 1180 Glu Leu Leu Gin Thr Cys He Asp Pro Glu Asp Cys Pro Val Cys Glu 1185 1190 1195 1200 Val Ala Gly Arg Arg Leu Ala Pro Gly Lys Lys He He Leu Asn Pro 1205 1210 1215 Ser Asp Pro Glu His Cys Gin He Cys Asn Cys Asp Gly Val Asn Phe 1220 1225 1230 Thr Cys Lys Ala Cys Arg Glu Pro Gly Ser Val Val Val Pro Pro Thr 1235 1240 1245 Asp Gly Pro He Gly Ser Thr Thr Ser Tyr Val Glu Asp Thr Ser Glu 1250 1255 1260 Pro Pro Leu His Asp Phe His Cys Ser Arg Leu Leu Asp Leu Val Phe 1265 1270 1275 1280 Leu Leu Asp Gly Ser Ser Lys Leu Ser Glu Asp Glu Phe Glu Val Leu 1285 1290 1295 Lys Val Phe Val Val Gly Met Met Glu His Leu His He Ser Gin Lys 1300 1305 1310 Arg He Arg Val Ala Val Val Glu Tyr His Asp Gly Ser His Ala Tyr 1315 1320 1325 He Glu Leu Lys Asp Arg Lys Arg Pro Ser Glu Leu Arg Arg He Thr 1330 1335 1340 Ser Gin Val Lys Tyr Ala Gly Ser Glu Val Ala Ser Thr Ser Glu Val 1345 1350 1355 1360 Leu Lys Tyr Thr Leu Phe Gin He Phe Gly Lys He Asp Arg Pro Glu 1365 1370 1375 Ala Ser Arg He Ala Leu Leu Leu Met Ala Ser Gin Glu Pro Ser Arg 1380 1385 1390 Leu Ala Arg Asn Leu Val Arg Tyr Val Gin Gly Leu Lys Lys Lys Lys 1395 1400 1405 Val He Val He Pro Val Gly He Gly Pro His Ala Ser Leu Lys Gin 1410 1415 1420 He His Leu He Glu Lys Gin Ala Pro Glu Asn Lys Ala Phe Val Phe 1425 1430 1435 1440 Ser Gly Val Asp Glu Leu Glu Gin Arg Arg Asp Glu He He Asn Tyr 1445 1450 1455 Leu Cys Asp Leu Ala Pro Glu Ala Pro Ala Pro Thr Gin His Pro Pro 1460 1465 1470 Met Ala Gin Val Thr Val Gly Ser Glu Leu Leu Gly Val Ser Ser Pro 1475 1480 1485 Gly Pro Lys Arg Asn Ser Met Val Leu Asp Val Val Phe Val Leu Glu 1490 1495 1500 Gly Ser Asp Lys He Gly Glu Ala Asn Phe Asn Lys Ser Arg Glu Phe 1505 1510 1515 1520 Met Glu Glu Val He Gin Arg Met Asp Val Gly Gin Asp Arg He His 1525 1530 1535 Val Thr Val Leu Gin Tyr Ser Tyr Met Val Thr Val Glu Tyr Thr Phe 1540 1545 1550 Ser Glu Ala Gin Ser Lys Gly Glu Val Leu Gin Gin Val Arg Asp He 1555 1560 1565 Arg Tyr Arg Gly Gly Asn Arg Thr Asn Thr Gly Leu Ala Leu Gin Tyr 1570 1575 1580 Leu Ser Glu His Ser Phe Ser Val Ser Gin Gly Asp Arg Glu Gin Val 1585 1590 1595 1600 Pro Asn Leu Val Tyr Met Val Thr Gly Asn Pro Ala Ser Asp Glu He 1605 1610 1615 Lys Arg Met Pro Gly Asp He Gin Val Val Pro He Gly Val Gly Pro 1620 1625 1630 His Ala Asn Val Gin Glu Leu Glu Lys He Gly Trp Pro Asn Ala Pro 1635 1640 1645 He Leu He His Asp Phe Glu Met Leu Pro Arg Glu Ala Pro Asp Leu 1650 1655 1660 Val Leu Gin Arg Cys Cys Ser Gly Glu Gly Leu Gin He Pro Thr Leu 1665 1670 1675 16B0 Ser Pro Thr Pro Asp Cys Ser Gin Pro Leu Asp Val Val Leu Leu Leu 1685 1690 1695 Asp Gly Ser Ser Ser He Pro Ala Ser Tyr Phe Asp Glu Met Lys Ser 1700 1705 1710 Phe Thr Lys Ala Phe He Ser Arg Ala Asn He Gly Pro Arg Leu Thr 1715 1720 1725 Gin Val Ser Val Leu Gin Tyr Gly Ser He Thr Thr He Asp Val Pro 1730 1735 1740 Trp Asn Val Ala Tyr Glu Lys Val His Leu Leu Ser Leu Val Asp Leu 1745 1750 1755 1760 Met Gin Gin Glu Gly Gly Pro Ser Glu He Gly Asp Ala Leu Ser Phe 1765 1770 1775 Ala Val Arg Tyr Val Thr Ser Glu Val His Gly Ala Arg Pro Gly Ala 1780 1785 1790 Ser Lys Ala Val Val He Leu Val Thr Asp Val Ser Val Asp Ser Val 1795 1800 1805 Asp Ala Ala Ala Glu Ala Ala Arg Ser Asn Arg Val Thr Val Phe Pro 1810 1815 1820 He Gly He Gly Asp Arg Tyr Ser Glu Ala Gin Leu Ser Ser Leu Ala 1825 1830 1835 1840 Gly Pro Lys Ala Gly Ser Asn Met Val Arg Leu Gin Arg He Glu Asp 1845 1850 1855 Leu Pro Thr Val Ala Thr Leu Gly Asn Ser Phe Phe His Lys Leu Cys 1860 1865 1870 Ser Gly Phe Asp Arg Val Cys Val Asp Glu Asp Gly Asn Glu Lys Arg 1875 1880 1885 Pro Gly Asp Val Trp Thr Leu Pro Asp Gin Cys His Thr Val Thr Cys 1890 1895 1900 Leu Pro Asp Gly Gin Thr Leu Leu Lys Ser His Arg Val Asn Cys Asp 1905 1910 1915 1920 Arg Gly Pro Arg Pro Ser Cys Pro Asn Gly Gin Pro Pro Leu Arg Val 1925 1930 1935 Glu Glu Thr Cys Gly Cys Arg Trp Thr Cys D ro Cys Val Cys Met Gly 1940 1945 1950 Ser Ser Thr Arg His He Val Thr Phe Asp Gly Gin Asn Phe Lys Leu 1955 I960 1965 Thr Gly Ser Cys Ser Tyr Val Leu Phe Gin Asn Lys Glu Gin Asp Leu 1970 1975 1980 Glu Val He Leu Gin Asn Gly Ala Cys Ser Pro Gly Ala Lys Glu Thr 1985 1990 1995 2000 Cys Met Lys Ser He Glu Val Lys His Asp Gly Leu Ser Val Glu Leu 2005 2010 2015 His Ser Asp Met Gin Met Thr Val Asn Gly Arg Leu Val Ser He Pro 2020 2025 2030 Tyr Val Gly Gly Asp Met Glu Val Asn Val Tyr Gly Thr He Met Tyr 2035 2040 2045 Glu Val Arg Phe Asn His Leu Gly His He Phe Thr Phe Thr Pro Gin 2050 2055 2060 Asn Asn Glu Phe Gin Leu Gin Leu Ser Pro Arg Thr Phe Ala Ser Lys 2065 2070 2075 2080 Thr Tyr Gly Leu Cys Gly He Cys Asp Glu Asn Gly Ala Asn Asp Phe 2085 2090 2095 He Leu Arg Asp Gly Thr Val Thr Thr Asp Trp Lys Ala Leu He Gin 2100 2105 2110 Glu Trp Thr Val Gin Gin Leu Gly Lys Thr Ser Gin Pro Val His Glu 2115 2120 2125 Glu Gin Cys Pro Val Ser Glu Phe Phe His Cys Gin Val Leu Leu Ser 2130 2135 2140 Glu Leu Phe Ala Glu Cys His Lys Val Leu Ala Pro Ala Thr Phe Tyr 2145 2150 2155 2160 Ala Met Cys Gin Pro Asp Ser Cys His Pro Lys Lys Val Cys Glu Ala 2165 2170 2175 He Ala Leu Tyr Ala His Leu Cys Arg Thr Lys Gly Val Cys Val Asp 2180 2185 2190 Trp Arg Arg Ala Asn Phe Cys Ala Met Ser Cys Pro Pro Ser Leu Val 2195 2200 2205 Tyr Asn His Cys Glu His Gly Cys Pro Arg Leu Cys Glu Gly Asn Thr 2210 2215 2220 Ser Ser Cys Gly Asp Gin Pro Ser Glu Gly Cys Phe Cys Pro Pro Asn 2225 2230 2235 2240 Gin Val Met Leu Glu Gly Ser Cys Val Pro Glu Glu Ala Cys Thr Gin 2245 2250 2255 Cys He Ser Glu Asp Gly Val Arg His Gin Phe Leu Glu Thr Trp Val 2260 2265 2270 Pro Ala His Gin Pro Cys Gin He Cys Thr Cys Leu Ser Gly Arg Lys 2275 2280 2285 Val Asn Cys Thr Leu Gin Pro Cys Pro Thr Ala Lys Ala Pro Thr Cys 2290 2295 2300 Gly Pro Cys Glu Val Ala Arg Leu Arg Gin Asn Ala Val Gin Cys Cys 2305 2310 2315 2320 Pro Glu Tyr Glu Cys Val Cys Asp Leu Val Ser Cys Asp Leu Pro Pro 2325 2330 2335 Val Pro Pro Cys Glu Asp Gly Leu Gin Met Thr Leu Thr Asn Pro Gly 2340 2345 2350 Glu Cys Arg Pro Asn Phe Thr Cys Ala Cys Arg Lys Asp Glu Cys Arg 2355 2360 2365 Arg Glu Ser Pro Pro Ser Cys Pro Pro His Arg Thr Pro Ala Leu Arg 2370 2375 2380 Lys Thr Gin Cys Cys Asp Glu Tyr Glu Cys Ala Cys Asn Cys Val Asn 2385 2390 2395 2400 Ser Thr Val Ser Cys Pro Leu Gly Tyr Leu Ala Ser Ala Val Thr Asn 2405 2410 2415 Asp Cys Gly Cys Thr Thr Thr Thr Cys Phe Pro Asp Lys Val Cys Val 2420 2425 2430 His Arg Gly Thr He Tyr Pro Val Gly Gin Phe Trp Glu Glu Ala Cys 2435 2440 2445 Asp Val Cys Thr Cys Thr Asp Leu Glu Asp Ser Val Met Gly Leu Arg 2450 2455 2460 Val Ala Gin Cys Ser Gin Lys Pro Cys Glu Asp Asn Cys Leu Ser Gly 2465 2470 2475 2480 Phe Thr Tyr Val Leu His Glu Gly Glu Cys Cys Gly Arg Cys Leu Pro 2485 2490 2495 Ser Ala Cys Glu Val Val Thr Gly Ser Pro Arg Gly Asp Ala Gin Ser 2500 2505 2510 His Trp Lys Asn Val Gly Ser His Trp Ala Ser Pro Asp Asn Pro Cys 2515 2520 2525 Leu He Asn Glu Cys Val Arg Val Lys Glu Glu Val Phe Val Gin Gin 2530 2535 2540 Arg Asn Val Ser Cys Pro Gin Leu Asn Val Pro Thr Cys Pro Thr Gly 2545 2550 2555 2560 Phe Gin Leu Ser Cys Lys Thr Ser Glu Cys Cys Pro Thr Cys His Cys 2565 2570 2575 Glu Pro Leu Glu Ala Cys Leu Leu Asn Gly Thr He He Gly Pro Gly 2580 2585 2590 Lys Ser Leu Met He Asp Val Cys Thr Thr Cys Arg Cys Thr Val Pro 2595 2600 2605 Val Gly Val He Ser Gly Phe Lys Leu Glu Gly Arg Lys Thr Thr Cys 2610 2615 2620 Glu Ala Cys Pro Leu Gly Tyr Lys Glu Glu Lys Asn Gin Gly Glu Cys 2625 2630 2635 2640 Cys Gly Arg Cys Leu Pro He Ala Cys Thr He Gin Leu Arg Gly Gly 2645 2650 2655 Gin He Met Thr Leu Lys Arg Asp Glu Thr He Gin Asp Gly Cys Asp 2660 2665 2670 Ser His Phe Cys Lys Val Asn Glu Arg Gly Glu Tyr He Trp Glu Lys 2675 2680 2685 Arg Val Thr Gly Cys Pro Pro Phe Asp Glu His Lys Cys Leu Ala Glu 2690 2695 2700 Gly Gly Lys He Met Lys He Pro Gly Thr Cys Cys Asp Thr Cys Glu 2705 2710 2715 2720 Glu Pro Glu Cys Lys Asp He He Ala Lys Leu Gin Arg Val Lys Val 2725 2730 2735 Gly Asp Cys Lys Ser Glu Glu Glu Val Asp He His Tyr Cys Glu Gly 2740 2745 2750 Lys Cys Ala Ser Lys Ala Val Tyr Ser He His Met Glu Asp Val Gin 2755 2760 2765 Asp Gin Cys Ser Cys Cys Ser Pro Thr Gin Thr Glu Pro Met Gin Val 2770 2775 2780 Ala Leu Arg Cys Thr Asn Gly Ser Leu He Tyr His Glu He Leu Asn 2785 2790 2795 2800 Ala He Glu Cys Arg Cys Ser Pro Arg Lys Cys Ser Lys 2805 2810

Claims: WE CLAIM: 1. An isolated nucleic acid comprising a nucleotide sequence encoding canine von Willebrand Factor polypeptide. 2. The isolated nucleic acid of Claim 1 , wherein the nucleotide sequence is capable of hybridizing under high stringency conditions to SEQ ID NO. 1. 3. The isolated nucleic acid of Claim 1 , wherein the nucleotide sequence encodes the Scottish terrier von Willebrand Factor polypeptide. 4. The isolated nucleic acid of Claim 2, wherein the nucleotide sequence encodes the Scottish terrier von Willebrand Factor polypeptide. 5. A vector comprising the nucleic acid of Claim 1. 6. A vector comprising the nucleic acid of Claim 2. 7. A cell comprising the vector of Claim 5. 8. A cell comprising the vector of Claim 6. 9. An isolated nucleic acid comprising a nucleotide sequence encoding defective canine von Willebrand Factor polypeptide. 10. The isolated nucleic acid of Claim 9, wherein the nucleotide sequence is capable of hybridizing under high stringency conditions to the complement of SEQ ID NO. 1 having a base deletion at codon 88. 1 1. A vector comprising the nucleic acid of Claim 9. 12. A vector comprising the nucleic acid of Claim 10. 13. A cell comprising the vector of Claim 1 1. 14. A cell comprising the vector of Claim 12. 15. An isolated oligonucleotide sequence consisting of contiguous nucleic acids of the nucleotide sequence of SEQ ID NO. 1 and capable of specifically hybridizing with the canine von Willebrand Factor gene. 16. An isolated oligonucleotide sequence consisting of contiguous nucleic acids of the nucleotide sequence that is complementary to the sequence of SEQ ID NO. 1 and capable of specifically hybridizing with the canine von Willebrand Factor gene. 17. A method of detecting a canine von Willebrand Factor gene in a sample comprising the steps of: a) contacting the sample with a oligonucleotide comprising contiguous nucleic acids of the nucleotide sequence of SEQ ID NO. 1 and capable of specifically hybridizing with the canine von Willebrand Factor gene, under conditions favorable for hybridization of the oligonucleotide to any complementary sequences of nucleic acid in the sample; and b) detecting hybridization, thereby detecting a canine von Willebrand Factor gene. 18. The method of Claim 17, further comprising the step of: c) quantifying hybridization of the oligonucleotide to complementary sequence. 19. The method of Claim 17, wherein in SEQ ID NO. 1 there is a base deletion at codon 88. 20. An assay kit for screening for a canine von Willebrand Factor gene comprising: a) an oligonucleotide comprising contiguous nucleic acids of the nucleotide sequence of SEQ ID NO. 1 and capable of hybridizing with the canine von Willebrand Factor gene; b) reagents for hybridization of the oligonucleotide to a complementary nucleic acid sequence; and c) container means for a)-b). 21. A method of detecting a canine von Willebrand Factor gene in a sample comprising the steps of: a) contacting the sample with an oligonucleotide comprising contiguous nucleic acids of the nucleotide sequence that is complementary to the sequence of SEQ ID NO. 1 and capable of specifically hybridizing to the complementary nucleotide sequence, under conditions favorable for hybridization of the oligonucleotide to any complementary sequences of nucleic acid in the sample; and b) detecting hybridization, thereby detecting a canine von Willebrand Factor gene. 22. The method of Claim 21 , further comprising the step of: c) quantifying hybridization of the oligonucleotide to complementary sequences. 23. The method of Claim 21 , wherein in SEQ ID NO. 1 there is a base deletion at codon 88. 24. An assay kit for screening for a canine von Willebrand Factor gene comprising: a) an oligonucleotide comprising contiguous acids from the nucleotide sequence that is complementary to the sequence of SEQ ID NO. 1 and capable of specifically hybridizing to the complementary nucleotide sequence; b) reagents for hybridization of the oligonucleotide to a complementary nucleic acid sequence; and c) container means for a)-b). 25. The assay kit of Claim 24, wherein in SEQ ID NO. 1 there is a base deletion at codon 88. 26. A method for detecting a mutated canine von Willebrand Factor gene in a canine DNA sample comprising the steps of: a) amplifying the DNA sample by polymerase chain reaction to produce polymerase chain reaction products, wherein the polymerase chain reaction uses primers that produce a restriction site in a mutant allele but not in a normal allele; b) digesting the polymerase chain reaction products with a restriction enzyme specific to the restriction site of the restriction site primer to produce DNA fragments; and c) detecting the DNA fragments, thereby detecting a mutated canine von Willebrand Factor gene. 27. The method of Claim 26, wherein the primers are those of Figure 4. 28. The method of Claim 26, wherein the DNA fragments are detected by gel electrophoresis. 29. The method of Claim 27, wherein the restriction enzyme is Ss/EI. 30. The method of Claim 27, wherein the restriction enzyme is Sat/96 I. 31. An oligonucleotide probe capable of detecting a mutation associated with canine von Willebrand's disease, wherein the mutation is a base deletion at codon 88 of the canine von Willebrand Factor gene.

Inventors: BREWER GEORGE J, SCHALL WILLIAM D, VENTA PATRICK J, YUZBASIYAN-GURKAN VILMA, BREWER, GEORGE, J., SCHALL, WILLIAM, D., VENTA, PATRICK, J., YUZBASIYAN-GURKAN, VILMA
Applicants: BREWER GEORGE J, SCHALL WILLIAM D, UNIV MICHIGAN, UNIV MICHIGAN STATE, VENTA PATRICK J, YUZBASIYAN GURKAN VILMA, BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERS, BREWER, GEORGE, J., SCHALL, WILLIAM, D., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, VENTA, PATRICK, J., YUZBASIYAN-GURKAN, VILMA
Application year: 1997
Main classification: C12Q1
IPC codes: C07K14, C12Q1